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Drivers Aged 16 or 17 Years 
Involved in Fatal Crashes — 
United States, 2004–2008
Motor vehicle crashes are the leading cause of death among 
teens in the United States, accounting for approximately one 
third of deaths in this age group (1). Crash risk is highest dur-
ing the first years of independent driving (2). To characterize 
trends in fatal crashes involving drivers aged 16 or 17 years, 
CDC analyzed data from the Fatality Analysis Report System 
(FARS) for 2004–2008. This report summarizes the results 
of that analysis, which indicated that, during 2004–2008, a 
total of 9,644 passenger vehicle drivers aged 16 or 17 years 
were involved in fatal crashes. During that period, the annual 
population-based rate for drivers aged 16 or 17 years involved 
in fatal crashes declined 38%, from 27.1 per 100,000 popula-
tion in 2004 to 16.7 in 2008. By state, 5-year annualized rates 
for drivers aged 16 or 17 years involved in fatal crashes ranged 
from 9.7 per 100,000 population in New Jersey and New York 
to 59.6 in Wyoming. To further reduce fatal crashes involving 
young drivers, states should periodically reexamine and update 
graduated driver licensing (GDL) programs, and communities 
should vigorously enforce laws on minimum legal drinking age, 
blood alcohol concentration (BAC), and safety belt use, all of 
which can reduce the number of fatal crashes among young 
drivers.
FARS is a census of fatal traffic crashes in the United 
States maintained by the National Highway Traffic Safety 
Administration. For this study, records of drivers involved in 
fatal crashes during 2004–2008 were examined. A fatal crash 
National Teen Driver Safety Week —  
October 17–23, 2010
In 2009, approximately 3,000 teens aged 15–19 years, 
died in motor vehicle crashes, approximately 500 fewer 
deaths than occurred in 2008 in this age group (1). During 
2004–2008, the percentage of drivers aged 16–17 years 
involved in fatal crashes decreased by 36% (2). Despite 
these encouraging trends, motor vehicle crashes remain the 
leading cause of death for teens.
Graduated driver licensing (GDL) programs are widely 
credited with contributing to recent declines in teen crash 
fatalities. Evaluations of GDL have demonstrated a 20%–
40% reduction in crash risk for the youngest drivers (3). 
GDL programs provide longer practice periods, limit driv-
ing under high-risk conditions for newly licensed drivers, 
and require greater participation of parents in their teens’ 
learning-to-drive process. This year, during National Teen 
Driver Safety Week, CDC is launching a new campaign, 
Parents Are the Key, to inform parents how they can help 
protect the safety of their teen drivers. Campaign materi-
als are available at http://www.cdc.gov/parentsarethekey. 
CDC also has released the issue brief Policy Impact: Teen 
Driver Safety, which is available at http://www.cdc.gov/
motorvehiclesafety/teenbrief.
Additional information regarding National Teen Driver 
Safety Week is available from CDC at http://www.cdc.gov/
motorvehiclesafety/teen_drivers/index.html and from the 
National Highway Traffic Safety Administration at http://
www.nhtsa.gov/Teen-Drivers.
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was defined as one in which at least one vehicle occu-
pant or nonoccupant (e.g., bicyclist or pedestrian) 
involved in the crash died within 30 days of the crash. 
Analyses were restricted to drivers of passenger vehicles 
(i.e., automobiles, sport utility vehicles, pickup trucks, 
and vans). Of the 10,048 drivers aged 16 or 17 years 
involved in fatal crashes, 9,644 (96%) drove passenger 
vehicles. U.S. census population estimates for persons 
aged 16 or 17 years and persons aged ≥18 years were 
used to calculate rates of fatal crash involvement. To 
examine state-specific rates for drivers aged 16 or 
17 years involved in fatal crashes, 2004–2008 crash 
data and census data were aggregated separately, and 
an annualized rate was calculated for each state. The 
annualized rates then were compared with 2008 
state-specific fatality rates for all crashes involving 
passenger vehicles.
During 2004–2008, a total of 9,644 drivers aged 
16 or 17 years were involved in 9,494 fatal crashes. 
A total of 4,705 (50%) crashes involved one vehicle; 
3,976 (42%) involved two vehicles; and 813 (8%) 
involved three or more vehicles. A total of 8,274 
(87%) crashes resulted in one fatality, 986 (10%) 
resulted in two fatalities, and 234 (3%) resulted in 
three or more fatalities.
Of the 11,019 persons who died in these crashes, 
4,071 (37%) were drivers aged 16 or 17 years; 3,428 
(31%) were passengers of those drivers; 1,987 (18%) 
were drivers of other vehicles (aged ≥18 years, aged 
<16 years, and of unknown age); and 805 (7.3%) 
were passengers of those other drivers. Another 728 
(6.7%) persons were other road users (e.g., bicyclists 
or pedestrians).
A total of 6,280 (65%) drivers aged 16 or 17 years 
involved in fatal crashes were male; 3,429 (36%) of 
drivers in the age group were reported speeding at the 
time of the crash. Of the 4,459 (46%) whose BAC 
levels were known, 3,512 (79%) had zero BAC. Of 
the 947 drivers with a positive BAC, levels ranged 
from 0.01 g/dL to 0.55 g/dL, with a median of 0.11 
g/dL; 678 (72%) of these drivers had a BAC of ≥0.08 
g/dL, above the legal limit for drivers aged ≥21 years. 
Drivers aged <21 years, who cannot purchase alcohol 
legally, are subject to lower BAC limits in every state 
(i.e., >0.00 g/dL, ≥0.01 g/dL, or ≥0.02 g/dL, depend-
ing on the state).
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From 2004 to 2008, the annual number of drivers 
aged 16 or 17 years involved in fatal crashes decreased 
36%, from 2,230 to 1,437 (Table 1). Continuing 
a general decline that began in 1996 (Figure), the 
population-based rate for drivers aged 16 or 17 years 
involved in fatal crashes decreased 38%, from 27.1 per 
100,000 population in 2004 to 16.7 in 2008 (Table 
1). During 2004–2008, year-to-year decreases in the 
rate ranged from 5% from 2005 to 2006 to 23% from 
2007 to 2008. In comparison, the rate for drivers aged 
≥18 years involved in fatal crashes declined 20%, 
from 20.5 per 100,000 population in 2004 to 16.3 
per 100,000 in 2008. Year-to-year declines in the rate 
of fatal crash involvement for drivers aged ≥18 years 
ranged from <1% from 2004 to 2005 to 12% from 
2007 to 2008 (Table 1).
Among states, the 5-year annualized rate for 
drivers aged 16 or 17 years involved in fatal crashes 
ranged from 9.7 per 100,000 population in New 
York and New Jersey to 59.6 in Wyoming (Table 2). 
These state-specific rates correlated strongly with 2008 
state-specific fatality rates from all crashes involving 
passenger vehicles (Pearson correlation coefficient = 
0.8) (Table 2).
Reported by
Shults RA, PhD, Ali B, MPH, Div of Unintentional 
Injury Prevention, National Center for Injury Prevention 
and Control, CDC.
Editorial Note
The results described in this report indicate that 
the population-based rate for drivers aged 16 or 17 
years involved in fatal crashes continued to decline 
substantially during 2004–2008, most notably 
from 2007 to 2008, when the rate decreased 23%. 
Among drivers aged ≥18 years, the rate decreased 
12% from 2007 to 2008. Reasons for the decreases 
in rates of involvement in fatal crashes are unknown 
but they have been attributed, in part, to decreases 
in the number of vehicle miles traveled (particularly 
discretionary travel) because of rising gasoline prices 
and adverse economic conditions (3). Economic 
downturns are believed to produce greater cutbacks in 
travel for drivers with limited funds, including teens 
(3). Additionally, some teens might delay obtaining 
drivers licenses for financial reasons during adverse 
economic conditions, reducing the number of overall 
miles driven by teens.
The decline during 2004–2008 in the rate of young 
drivers involved in fatal crashes extends a long-term 
downward trend (2). From 1996 to 2008, the rate for 
drivers aged 16 or 17 years involved in fatal crashes fell 
approximately 50%, from 36.0 per 100,000 popula-
tion (2) to 16.7. GDL programs are widely credited 
with contributing to this decline. A recent review of 
GDL evaluations concluded that the programs have 
reduced young driver crash risk by approximately 
20% to 40% (4). First implemented in the United 
States in 1996 in Florida, GDL programs now oper-
ate in 49 states and the District of Columbia.* The 
programs initially limit teens’ independent driving 
* Additional information available at http://www.iihs.org/laws/
graduatedlicenseintro.aspx.
FIGURE. Annual rate* for drivers† aged 16 or 17 years involved in fatal crashes, 
by age group — Fatality Analysis Reporting System, United States, 1990–2008
* Per 100,000 population in age group.
















16 or 17 yrs
Year




 2004  2005  2006 2007  2008 2004 to 2008
Total No. Rate No. Rate No. Rate No. Rate No. Rate No. change (%) Rate change (%)
16 or 17 9,644 2,230 27.1 2,054 24.5 2,020 23.4 1,903 21.8 1,437 16.7 -36 -38
≥18 214,054 45,145 20.5 45,360 20.4 43,963 19.6 42,143 18.5 37,443 16.3 -18 -20
* Per 100,000 population in age group.
† Of passenger vehicles (i.e., automobiles, sport utility vehicles, pickup trucks, and vans).
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TABLE 2. Number and 5-year annualized rate* for drivers† aged 16 or 17 years involved in fatal crashes and 2008 fatality rate from all crashes 
involving passenger vehicles, by state§ — Fatality Analysis Reporting System, United States, 2004–2008
State 2004 2005 2006 2007 2008
5-year annualized rate, 
2004–2008¶
Fatality rate from all crashes involving 
passenger vehicles, 2008¶
Alabama 80 63 71 53 45 48.0 18.7
Alaska 4 1 5 10 4 21.4 7.4
Arizona 58 40 47 33 35 24.5 11.9
Arkansas 41 35 35 28 24 40.9 18.2
California 145 143 136 130 67 11.6 8.0
Colorado 50 33 29 30 21 25.0 9.5
Connecticut 19 13 12 12 12 13.8 6.3
Delaware 16 8 6 8 4 35.8 12.4
District of Columbia 3 0 0 0 0 —** 4.6
Florida 140 149 137 138 110 28.8 14.1
Georgia 79 85 83 83 66 29.2 13.6
Hawaii 9 2 3 1 2 — 6.8
Idaho 13 21 15 15 9 32.7 13.1
Illinois 78 69 86 80 31 18.9 7.1
Indiana 73 57 59 49 47 31.6 11.3
Iowa 29 26 27 33 16 30.9 11.9
Kansas 26 29 25 30 19 31.9 11.9
Kentucky 50 50 52 37 31 38.2 16.7
Louisiana 59 27 34 37 30 28.4 18.7
Maine 16 6 18 10 6 30.1 9.9
Maryland 39 38 31 29 31 20.7 9.5
Massachusetts 25 23 27 22 13 12.6 4.9
Michigan 76 58 50 63 47 19.6 8.8
Minnesota 47 43 42 29 22 24.4 7.4
Mississippi 47 55 41 40 26 47.6 25.0
Missouri 80 83 64 57 48 39.4 14.6
Montana 6 6 6 4 13 25.0 19.7
Nebraska 18 20 21 28 18 40.8 10.4
Nevada 15 19 16 13 11 22.1 10.7
New Hampshire 17 4 6 12 4 22.6 9.2
New Jersey 12 33 33 18 21 9.7 6.1
New Mexico 19 19 18 12 17 29.2 15.6
New York 65 58 53 55 33 9.7 5.3
North Carolina 89 79 72 86 57 31.9 14.0
North Dakota 3 2 13 10 6 37.7 13.4
Ohio 73 73 73 61 62 20.7 8.9
Oklahoma 42 42 39 37 31 37.4 18.2
Oregon 18 19 15 18 5 14.7 9.5
Pennsylvania 78 71 60 82 55 19.8 9.9
Rhode Island 6 6 5 6 3 18.0 5.4
South Carolina 41 36 51 39 30 32.0 18.4
South Dakota 6 8 10 8 12 37.3 13.1
Tennessee 67 69 61 56 42 35.4 15.0
Texas 172 161 145 149 121 21.6 11.9
Utah 22 17 21 15 9 20.2 8.5
Vermont 6 3 6 4 4 25.4 11.1
Virginia 57 48 49 42 48 23.5 9.6
Washington 20 25 38 28 19 14.4 6.8
West Virginia 13 14 15 12 9 27.1 18.5
Wisconsin 56 55 50 39 34 29.0 9.3
Wyoming 7 10 9 12 7 59.6 24.8
 * Per 100,000 population in age group.
 † Of passenger vehicles (i.e., automobiles, sport utility vehicles, pickup trucks, and vans).
 § Includes District of Columbia.
 ¶ Pearson correlation coefficient = 0.8. Compares state-level annualized rates for drivers aged 16 or 17 years involved in fatal crashes during 2004–2008 with 2008 
fatality rates from all crashes involving passenger vehicles. 
 ** Rates suppressed because numerators were <20.
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under various high-risk conditions, such as nighttime 
driving or carrying teen passengers. All U.S. GDL 
programs include a nighttime driving restriction, and 
42 states and the District of Columbia include a teen 
passenger restriction. CDC recommends that families 
of newly licensed teen drivers actively enforce GDL 
requirements with a parent-teen driving contract (5). 
Other factors that likely contributed to the long-term 
decline in fatal crashes involving young drivers include 
improvements in vehicle and road safety, increased 
seat belt use, and reductions in driving after drinking 
alcohol (6).
State-specific rates of drivers aged 16 or 17 years 
involved in fatal crashes varied by sixfold. By state, 
the strong correlation between rates for young driv-
ers involved in fatal crashes and fatality rates from 
all crashes involving passenger vehicles suggests that 
state-specific differences in the driving environment 
(e.g., degree of urbanization, speed limits, amounts 
and types of travel, weather, state traffic laws, rates 
of licensure, and emergency-care capabilities) have 
similar effects on fatal crash risk for drivers of all 
ages.† The relatively low rates of crash involvement 
for young drivers in New Jersey and New York might 
be related to licensing policies. New Jersey is the only 
state with a minimum licensing age of 17 years; in 
New York City, the minimum age is 18 years, except 
for persons who take a state-approved driver educa-
tion course and meet other requirements, who may 
be licensed at aged 17 years.
The findings in this report are subject to at least 
four limitations. First, population-based crash rates do 
not account for driving exposure. This limitation is of 
particular concern because the age at which teens may 
begin to drive independently varies by state from 14 
years to 17 years; therefore, the proportion of persons 
aged 16 or 17 years who are eligible to drive without 
adult supervision varies widely by state. Ideally, stud-
ies of young driver crash risk would include measures 
such as the number of miles driven or number of 
licensed teen drivers. Reliable data on these driv-
ing exposure measures are not readily available for 
research (2,7). To help facilitate collection of data on 
driving exposure, the Transportation Research Board’s 
Subcommittee on Young Drivers recently identified 
documenting the amount and type of driving done 
by teens as one of five high-priority research needs 
(7). Second, the two variables used in calculating the 
Pearson correlation coefficient were not completely 
independent because fatalities resulting from crashes 
involving drivers aged 16 or 17 years were included 
in the 2008 state-specific fatality rates for all crashes 
involving passenger vehicles. The effect is small, how-
ever, because only 5% of passenger vehicle fatalities in 
2008 involved a driver aged 16 or 17 years. Third, any 
fatalities that occur >30 days postcrash are excluded 
from FARS. Finally, caution should be used in inter-
preting the differences in fatal crash involvement rates 
among states because many factors that vary by state 
contribute to crash risk.
GDL programs vary in makeup; the more com-
prehensive programs are associated with larger crash 
reductions (8). To further reduce crashes among 
young drivers, states should ensure that their GDL 
programs include all of the components with dem-
onstrated effectiveness, including extended learner 
periods, nighttime driving restrictions, and pas-
senger restrictions (9). As GDL programs evolve 
and additional evaluation results become available, 
states should reexamine their programs and consider 
implementing additional components that have been 
proven effective. Additionally, communities should 
vigorously enforce existing laws known to be effective 
among young drivers and the general driving popula-
tion, including laws on minimum legal drinking age, 
BAC, and safety belt use. Information regarding the 
effectiveness of these strategies is available at http://
www.thecommunityguide.org/mvoi/index.html.
What is already known on this topic?
Teen drivers have the highest motor vehicle crash risk 
of any age group, and crashes are the leading cause of 
death among teens in the United States.
What is added by this report?
The national rate for drivers aged 16 or 17 years 
involved in fatal crashes declined 38% from 2004 to 
2008 to 16.7 per 100,000 population; however, rates 
among states ranged from 9.7 to 59.6.
What are the implications for public health practice?
To further reduce crashes among young drivers, states 
should ensure that their graduated driver licensing 
programs include all effective measures, including 
extended learner periods, nighttime driving restric-
tions, and passenger restrictions.
† Additional information available at http://www.iihs.org/research/
fatality_facts_2008/statebystate.html.
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was found to be HIV infected, and an investigation 
determined that the patient’s infection was acquired 
from the donor’s blood products. Even though such 
transmissions are rare, health-care providers should 
consider the possibility of transfusion-transmitted 
HIV in HIV-infected transfusion recipients with no 
other risk factors.
Case Reports
Donor. In June 2008, a man in his forties donated 
whole blood at a blood center in Missouri (Figure 1). 
He was a repeat blood donor who reported no HIV 
risk factors on the routine eligibility screening ques-
tionnaire. He was not compensated for his blood 
donation. His whole blood donation was screened at 
a reference laboratory for HIV by enzyme immuno-
assay (EIA) (Genetic Systems HIV-1/HIV-2 Plus O 
EIA, Bio-Rad Laboratories, Redmond, Washington) 
and by nucleic acid amplification testing of minipools 
of plasma specimens (MP-NAT) from 16 donations 
(Procleix HIV-1 Nucleic Acid Test, Gen Probe, 
San Diego, California); both tests were negative. 
Transmission of human immunodeficiency 
virus (HIV) through transfusion of contami-
nated blood components was documented in the 
United States in 1982 (1). Since then, the risk for 
transfusion-transmitted HIV infection has been almost 
eliminated by the use of questionnaires to exclude 
donors at higher risk for HIV infection and the use of 
highly sensitive laboratory screening tests to identify 
infected blood donations. The risk for acquiring HIV 
infection through blood transfusion today is estimated 
conservatively to be one in 1.5 million, based on 
2007–2008 data (2). This report describes the first 
U.S. case of transfusion-transmitted HIV infection 
reported to CDC since 2002 (3). A blood center in 
Missouri discovered that blood components from a 
donation in November 2008 tested positive for HIV 
infection. A lookback investigation determined that this 
donor had last donated in June 2008, at which time 
he incorrectly reported no HIV risk factors and his 
donation tested negative for the presence of HIV. One 
of the two recipients of blood components from this 
donation, a patient undergoing kidney transplantation, 
HIV Transmission Through Transfusion — 
Missouri and Colorado, 2008
FIGURE 1. Sequence of events for a case of transfusion-transmitted HIV infection — Missouri and Colorado, 2008 
Abbreviations: HIV = human immunodeficiency virus; NAT = nucleic acid amplification testing; MDHSS = Missouri Department of Health and Senior Services; 
CDPHE = Colorado Department of Public Health and Environment.
Day
0 28 56 84 112 140 196 224168 252 280 308 336 364
Day 179: Transplant surgeon for recipient B notied that the donor 
of the fresh frozen plasma had tested positive for HIV infection
Day 358: Donor 
enrolls in 
HIV care
Day 301: Donor agrees to 
be interviewed by MDHSS, 
and conrmatory testing 
is completed (April 2009)
Day 253: CDPHE completes investigation 
and sends results to CDC
Day 182: Recipient B has virologic evidence of 
HIV infection; antiretroviral therapy is initiated
Day 175: MDHSS notied of donor with possible HIV infection
Day 168: NAT for donor’s blood tests 
positive for HIV infection; blood bank 
initiates lookback investigation of 
previous donations
Day 69: Recipient B receives 
fresh frozen plasma during 
kidney transplant
Day 0: Donor’s rst blood donation (June 2008)
Day 35: Recipient A dies from complications of illness
Day 33: Recipient A receives red blood cells
Day 162: Donor’s second blood 
donation (November 2008)
14 42 70 98 126 154 210 238182 266 294 322 350
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Components from this donation later were trans-
fused into two recipients. No specimens from this 
donation were stored. In November 2008, the man 
donated blood again at the same blood center and 
again reported no risk factors on the routine eligibility 
screening questionnaire. At that time, his blood tested 
positive for HIV by EIA, MP-NAT, and indirect 
immunofluorescence assay (Fluorognost HIV-1 IFA, 
Sanochemia Corporation, Vienna, Austria). The man 
was placed on the list of donors who are indefinitely 
ineligible for future donation, all products from this 
donation were destroyed, and the man was notified by 
the blood center of his probable HIV infection. The 
Missouri Department of Health and Senior Services 
(MDHSS) was notified of this case on December 4, 
2008. Because of the rare possibility that the donor 
might have been infected shortly before his June 2008 
donation and donated blood that contained HIV at 
a concentration too low to be detected, an investiga-
tion was initiated to determine whether recipients 
of the June donation had been infected with HIV, 
consistent with regulatory requirements to investigate 
such events.
Initially, the donor declined repeated contacts by 
MDHSS to be interviewed. In April 2009, he agreed 
to a brief interview with MDHSS, and an OraQuick 
rapid HIV test (OraSure Technologies, Bethlehem, 
Pennsylvania) was performed. This test was reactive 
and confirmed by a positive Western blot at MDHSS. 
During his interview, the donor reported he was mar-
ried but had sex with both men and women outside 
of his marriage, including just before his June 2008 
donation. He indicated that the sex often was anony-
mous and occurred while he was intoxicated.
Recipients. The investigation initiated by the 
blood center identified two recipients of blood 
components (packed red blood cells and fresh frozen 
plasma) derived from the donor’s June 2008 donation. 
In July 2008, one unit of packed red blood cells from 
the donor was transfused into a patient in Arkansas 
during cardiac surgery. This patient died 2 days later 
from cardiac disease; no premortem or postmortem 
material was available for testing, and it was unknown 
whether the patient had been infected with HIV.
In August 2008, one unit of fresh frozen plasma 
from the donor was transfused into a patient receiving 
a kidney transplant in Colorado. The recipient’s most 
recent negative serum test for HIV infection (using 
HIV EIA) was in July 2005. The patient had been 
receiving regular hemodialysis for management of 
kidney failure since July 2005. From that date to the 
date of kidney transplantation, the patient reported no 
behavioral or health-care–related risk factors for HIV 
infection and did not received blood components. The 
kidney donor tested negative for HIV infection by 
EIA and NAT at the time of organ donation.
In December 2008, MDHSS notified the Colorado 
Department of Public Health and Environment 
(CDPHE) that the plasma was from a donor who 
subsequently tested positive for HIV, and CDPHE 
notified the recipient’s transplant surgeon. When the 
recipient visited the transplant clinic in December 
2008, serum was nonreactive by HIV EIA, but plasma 
HIV RNA viral load was 7,240 copies/mL, and CD4 
cell count was very low (48 cells/µL). At this time, 
the recipient was placed on antiretroviral therapy. The 
patient also was receiving mycophenolic acid, a drug 
used to prevent rejection in organ transplantation 
that is also a potent inhibitor of both lymphocyte 
proliferation and HIV replication in CD4+ T cells 
and macrophages. Physical examination demonstrated 
no other signs or symptoms of HIV infection. After 
antiretroviral therapy was initiated, the patient’s HIV 
RNA viral load became undetectable, and CD4 cell 
count increased to 88 cells/µL in June 2009. HIV EIA 
repeated in April 2009 was reactive, but the Western 
blot was indeterminate, with reactivity to the nonviral 
p38 and p42 bands and weak reactivity to gp120.
HIV DNA from blood specimens collected 
from the donor and the recipient was amplified and 
sequenced at CDC. Comparison of these sequences 
demonstrated that the virus from the donor and 
recipient were greater than 99% identical, confirming 
that the donor’s 2008 donation was the source of the 
recipient’s HIV infection.
Reported by
B Laffoon, Missouri Dept of Health and Senior Svcs. 
A Crutchfield, Colorado Dept of Public Health and 
Environment. M Levi, MD, Univ of Colorado at 
Denver. WA Bower, MD, M Kuehnert, MD, Office 
of Blood, Organ, and Other Tissue Safety, Div Health 
Care Quality Promotion, National Center for Emerg-
ing and Zoonotic Infectious Diseases; JT Brooks, MD, 
RM Selik MD, WM Switzer, MPH, W Heneine, PhD, 
A Shankar, MS, MSc, AD Iuliano, PhD, Div of HIV/
AIDS Prevention, National Center for HIV, Hepatitis, 
STD, and Tuberculosis Prevention, CDC.
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Editorial Note
This report describes the first U.S. case of trans-
fusion-transmitted HIV infection reported* to CDC 
since 2002 (3) (Figure 2). The sequence of events in 
this case is consistent with transmission by transfu-
sion of HIV-contaminated plasma collected from a 
donor during the eclipse period of acute infection 
(i.e., the interval between infection and the develop-
ment of detectable concentrations of HIV RNA in 
plasma) to a recipient treated with medication that 
suppressed HIV replication, reduced the CD4 lym-
phocyte count, and blunted the humoral response to 
HIV infection.
In 1999, U.S. blood banks implemented HIV 
NAT for blood donations to reduce HIV transmis-
sion from recently infected donors. NAT can detect 
the presence of HIV earlier in the course of infection 
than serologic methods, which only detect antibodies 
against HIV, thus reducing the window period (i.e., 
the interval between infection and development of 
detectable HIV markers in blood) from 22 days to 
approximately 10–15 days (4,5). However, NAT 
cannot detect HIV infections during the eclipse 
period, estimated to average 9 days based on limited 
data (6).
The Food and Drug Administration (FDA) 
requires blood centers to assess donor eligibility 
using a screening questionnaire and to test donations 
for infections to reduce the risk for transfusion-
transmitted disease.† FDA currently requires testing 
blood donations for HIV using both licensed serologic 
testing and NAT, which can detect HIV RNA at a 
minimum concentration of approximately 5.5 copies/
mL.§ NAT can be conducted on individual specimens 
(ID-NAT) or pooled specimens (MP-NAT). The 
number of specimens pooled for MP-NAT is based 
on manufacturer’s specifications and FDA’s test sen-
sitivity requirements.¶ The dilution effect inherent 
in screening by MP-NAT makes this method slightly 
less sensitive than ID-NAT (3.8 compared with 6.9 
infections prevented per year, respectively); however, 
ID-NAT is substantially less cost effective (7).
Widespread adoption of effective HIV testing 
methods to screen donated blood has greatly reduced 
the risk for transfusion-transmitted HIV infection. 
The modeled risk for HIV infection from transfu-
sion of blood products in the United States declined 
from one in 450,000–600,000 donations in 1995 
to one in 2,135,000 donations from 1995 to 2001 
after the introduction of NAT in 1999 (8) and was 
recently updated to one in 1,467,000 based on data 
from 2007–2008, which incorporates the increased 
incidence of HIV among blood donors (2). However, 
even the most sensitive screening technologies cur-
rently available cannot identify the presence of HIV 
infection during the first few days after infection, 
when neither HIV RNA nor HIV-specific antibodies 
have reached detectable levels.
Transfusion-transmitted HIV infection, although 
rare, likely is underrecognized, and every case warrants 
a detailed investigation. Three previous cases of HIV 
infection attributable to transfusion of infected blood 
products that tested negative by HIV NAT and EIA 
because of donation during the eclipse period were 
identified and reported to CDC in 2000 (9) and 2002 
(10). Assuming that 16 million donations occur each 
year** and using the most conservative estimated risk 
* A suspected case of transfusion-transmitted HIV infection in the 
United States in 2006 has been identified by a blood center through 
donor screening, but not reported to national surveillance.
† Additional information available at http://www.fda.gov/bio 
logicsbloodvaccines/guidancecomplianceregulatoryinformation/
guidances/blood/ucm073445.htm.




¶ Additional information available at http://www.fda.gov/down 
loads/biologicsblood%20vaccines/guidancecomplianceregulatory 
information/guidances/blood/ucm210270.pdf.
FIGURE 2. Number of cases of transfusion-transmitted HIV infection from con-

















 ** Additional information available at http://www.hhs.gov/ophs/blood 
safety/2007nbcus_survey.pdf.
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for HIV infection of one in 1.5 million donations (2), 
approximately 11 infectious donations and 20 HIV-
positive blood components released each year could 
potentially infect recipients. In this case, eligibility 
screening questions,†† if answered accurately, would 
have excluded the donor because of his sexual history. 
It is the responsibility of persons who donate blood to 
answer screening questionnaires accurately to ensure 
the safest blood supply possible.
Blood collection centers conduct investigations of 
previous donations when a positive antibody or NAT 
result is identified in a repeat donor. However, fewer 
than the expected number of cases of transfusion-
transmitted HIV infection were reported to CDC 
from 2002 to 2008, a 6-year period when an estimated 
16 million units of blood or blood components were 
donated annually. Because the number of reported 
cases is lower than expected, risk estimates might have 
been too high. Alternatively, transfusion-transmitted 
HIV infections might have gone unreported either 
because of 1) recipient death attributed to the under-
lying condition or some other cause before detection 
of HIV infection from the receipt of infected blood 
or blood components, 2) poor recall by infected per-
sons regarding receipt of blood or blood components 
What is already known on this topic?
Transfusion-transmitted cases of HIV infection are 
rare, but still might occur despite screening question-
naires for deferral of at-risk donations and improve-
ments in laboratory testing for detecting HIV in blood 
products.
What is added by this report?
This report describes the first case of transfusion-
transmitted HIV infection reported to CDC since 2002.
What are the implications for public health practice?
Although transfusion-transmitted HIV infection is a 
rare event, clinicians and health departments should 
evaluate the possibility of such an event in a patient 
with no other known risk factors for HIV infection. If a 
case of transfusion-transmitted HIV infection is identi-
fied, clinicians should report the case through their 
public health surveillance system and collaborate 
with blood collection centers and health departments 
to conduct an investigation.
before their HIV diagnosis, 3) inability to confirm 
or rule out transfusion as the source of infection 
because no HIV-infected donors were identified, 4) 
underrecognition of HIV infections among recipients 
of potentially infected blood or blood components 
who recover and might never have been subsequently 
tested for HIV infection, or 5) misclassification of a 
transfusion-transmitted HIV infection in a person 
who also had other risk factors more frequently asso-
ciated with HIV transmission (e.g., male-to-male 
sexual contact or injection drug use) to which that 
infection was attributed. Adoption of CDC’s 2006 
recommendation for routine opt-out HIV testing 
recommendations, whereby all persons are tested 
for HIV as part of routine health care unless they 
decline, might reduce the possibility of unrecognized 
transfusion-transmitted infections and possibly reduce 
donations by HIV-infected persons being made aware 
of their status.§§ Additionally, blood centers might 
consider the logistics, costs, and potential benefits of 
saving specimens of blood so that retrospective test-
ing can be conducted if transfusion-transmitted HIV 
infection is suspected.
Although the risk for transfusion-transmitted 
HIV infection is extremely low in the United States, 
transfusion should be considered along with other 
possible sources of HIV infection in a patient who 
has no other HIV risk factors. These investigations 
are most effective if conducted as soon as they are 
recognized and in collaboration with the blood center, 
transfusing health-care facilities, and state and local 
health departments. The National Healthcare Safety 
Network (NHSN) is a voluntary, secure, Internet-
based surveillance system designed to collect data 
from a sample of U.S. health-care facilities to permit 
valid estimation of the magnitude of adverse events 
among patients. The Hemovigilance Module added 
this year to the NHSN’s Biovigilance Component¶¶ 
was designed specifically to bolster the collaborative 
capacity of public health and private industry to detect 
adverse events (e.g., HIV infections) associated with 
transfusion. Findings from Hemovigilance Module 
surveillance data will be used to improve the safety 
of the blood supply in the United States.
 §§ Additional information available at http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr55/14a1.htm.
 ¶¶ Additional information available at http://www.cdc.gov/nhsn/bio.
html.
 †† Additional information available at http://www.fda.gov/
biologicsbloodvaccines/bloodbloodproducts/approvedproducts/
licensedproductsblas/blooddonorscreening/ucm164185.htm.
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directed to relevant contacts in each state via telephone 
or e-mail. The response rate was 100%. To validate 
survey responses, Medicaid programs were asked to 
submit documentation of their tobacco-dependence 
treatment coverage policies. Of the 47 programs 
that indicated they covered at least one tobacco-
dependence treatment, supporting documentation 
was obtained for 44 (94%) programs. For programs 
without complete documentation, the information 
given by the respondent was confirmed with a second 
respondent within that state before being accepted 
as accurate.
Among the 51 Medicaid programs, 47 provided 
tobacco-dependence treatment coverage for some 
enrollees, 38 covered at least one tobacco-dependence 
treatment for all Medicaid enrollees, and four 
(Connecticut, Georgia, Missouri, and Tennessee) 
offered no coverage for tobacco-dependence treat-
ment to their enrollees. Coverage for all enrollees 
was defined as coverage that did not differ between 
fee-for-service (FFS) and managed-care organization 
(MCO) enrollees. Coverage for all Medicaid enrollees 
was reported for the nicotine patch (34 programs), 
bupropion or Zyban* (33 programs), nicotine gum 
(32 programs), varenicline (Chantix) (32 programs), 
nicotine nasal spray (28 programs), nicotine inhalers 
(27 programs), and nicotine lozenges (25 programs). 
Only five states (Indiana, Massachusetts, Minnesota, 
Montana, and Pennsylvania) reported having policies 
that require coverage of all recommended pharmaco-
therapies and individual and group counseling for all 
Medicaid enrollees.
The 2008 Public Health Service guideline identi-
fies four combination therapies (i.e., two tobacco-
dependence medications taken simultaneously) as 
being effective in treating tobacco-dependence: 1) 
nicotine patch and nicotine gum, 2) nicotine patch 
and nicotine nasal spray, 3) nicotine patch and nico-
tine inhaler, and 4) nicotine patch and bupropion 
SR (3). The most commonly covered combination of 
tobacco-dependence treatments among the Medicaid 
Medicaid enrollees have nearly twice the smoking 
rates (37%) of the general adult population (21%), 
and smoking-related medical costs are responsible 
for 11% of Medicaid expenditures (1,2). In 2008, 
the Public Health Service released clinical practice 
guidelines recommending comprehensive coverage 
of effective tobacco-dependence medications and 
counseling by health insurers (3). Healthy People 2010 
established a clear objective for Medicaid programs 
to cover all Food and Drug Administration–approved 
medications and counseling for tobacco cessation (4). 
To monitor progress toward that objective, the Center 
for Health and Public Policy Studies at the University 
of California, Berkeley, in collaboration with CDC, 
surveyed Medicaid programs in the 50 states and 
the District of Columbia (DC) to document their 
2009 tobacco-dependence treatment coverage and 
found that 47 programs offered coverage. Only eight 
state programs offered coverage of all recommended 
pharmacotherapy and counseling for all Medicaid 
enrollees, and 16 programs reported coverage for fee-
for-service enrollees that differed from that provided 
for Medicaid managed-care enrollees. Among the 
33 programs that covered at least one combination 
therapy, the nicotine patch plus bupropion slow 
release (SR) was the one combination covered by all. 
The Affordable Care Act mandates Medicaid coverage 
of tobacco-dependence treatments (5) for pregnant 
women, beginning October 1, 2010. Coverage of 
pharmacotherapy for all Medicaid enrollees will be 
enhanced by January 2014, when states no longer 
may exclude tobacco-dependence cessation drugs 
from covered benefits. Monitoring the extent to which 
Medicaid programs place limitations on these treat-
ments can help in evaluating accessibility of tobacco-
dependence treatments to Medicaid enrollees.
Medicaid coverage of tobacco-dependence treat-
ments has been assessed regularly since 1998 by the 
University of California, Berkeley. In November 
2009, a link to an online survey instrument was sent 
to previously identified Medicaid personnel for the 
50 state Medicaid programs and DC. Respondents 
were asked to complete 45 questions regarding treat-
ment coverage, coverage limitations, outreach activi-
ties, and related subjects. Follow-up questions were 
State Medicaid Coverage for Tobacco-Dependence Treatments — 
United States, 2009
* Zyban is a trade name for bupropion. Coverage was assessed 
separately for Zyban and bupropion because some programs cover 
one but not the other. Data presented represent coverage for either 
bupropion or Zyban.
MMWR  Morbidity and Mortality Weekly Report
 MMWR  /  October 22, 2010  /  Vol. 59  /  No. 41 1341 
programs was the nicotine patch and bupropion SR 
(33 programs), followed by the nicotine patch and 
nicotine gum (21 programs), the nicotine patch and 
nicotine inhaler (21 programs), and the nicotine patch 
and nicotine nasal spray (19 programs).
Fewer Medicaid programs covered counseling than 
pharmacotherapy; 18 programs covered individual 
counseling for all Medicaid enrollees, six programs 
covered only FFS enrollees (with two restricting 
coverage to pregnant women), one covered MCO 
enrollees only, and six covered only pregnant women. 
Eight Medicaid programs covered group counseling 
for all Medicaid enrollees, three programs covered 
group counseling for FFS only (with two restricting 
coverage to pregnant women), two programs covered 
only MCO enrollees, and five programs covered group 
counseling for pregnant women only.†
Nationwide, coverage for any tobacco-dependence 
treatments increased, from 45 programs (including 
two with coverage only for pregnant women) to 47 
programs since 2007, the most recent year for which 
comparable data were reported (6). Nebraska added 
coverage for tobacco-dependence treatments for FFS 
enrollees and Alabama added individual counseling 
for pregnant women (Table). In addition, Arizona and 
Washington expanded coverage previously limited to 
pregnant women to include all Medicaid enrollees. 
Overall, 12 Medicaid programs added or expanded 
coverage from 2007 to 2009.
Medicaid enrollment options vary considerably 
across and within states. Some states offer only tra-
ditional FFS Medicaid, others enter into contracts 
with MCOs to provide services to Medicaid enroll-
ees. Because some state programs reported different 
coverage policies for FFS and MCO enrollees, and 
for pregnant women, Medicaid recipients within a 
state might have varying degrees of access to tobacco-
dependence treatments. Some states required that all 
MCO contracts provide an agreed upon level of cover-
age for tobacco-dependence treatments; other states 
allow MCOs to determine what coverage they offer. 
For example, 32 Medicaid programs covered nico-
tine gum to all enrollees, but nine programs offered 
coverage for nicotine gum to their FFS population 
without requirements to provide this coverage in their 
MCO contracts (Table). In addition, Rhode Island 
required coverage for nicotine gum in contracts with 
MCOs, but does not cover this treatment for FFS 
enrollees. Overall, 16 programs reported coverage 
for FFS enrollees that differed from that provided 
for MCO enrollees.
Reported by
SB McMenamin, PhD, HA Halpin, PhD, M Ingram, 
Center for Health and Public Policy Studies, Univ of 
California, Berkeley. A Rosenthal, Office on Smoking and 
Health, National Center for Chronic Disease Prevention 
and Health Promotion, CDC.
Editorial Note
This report updates previously published informa-
tion on coverage for tobacco-dependence treatments 
in Medicaid programs (6) and, for the first time, lists 
coverage for FFS, MCO, or all enrollees for each 
tobacco-dependence treatment in each Medicaid 
program and provides data on combination therapies. 
Coverage increased in 12 states since 2007, and in 
16 states, coverage for FFS enrollees differed from 
coverage for MCO enrollees.
Public health initiatives and clinical guidelines 
to reduce tobacco use have called for comprehensive 
coverage of recommended treatments (3,4). Most state 
Medicaid programs fall short of this goal. Coverage 
† Two programs covered counseling for pregnant women in FFS only. 
These two are included under the totals for pregnancy only and for 
FFS only (Table).
What is already known on this topic?
Prevalence of smoking is nearly twice as high among 
Medicaid enrollees than in the general U.S. popula-
tion, and Healthy People 2010 calls for expanding cov-
erage for tobacco-dependence treatment to Medicaid 
programs in all 50 states and the District of Columbia.
What is added by this report?
Although 47 (92%) of 51 Medicaid programs offered 
coverage for some form of tobacco-dependence 
treatment to Medicaid enrollees, only five states offer 
coverage of all recommended pharmacotherapies 
and individual and group counseling for all Medicaid 
enrollees, and 16 states have coverage policies that 
are not consistent for fee-for-service and managed-
care organization enrollees.
What are the implications for public health practice?
To increase the effectiveness of recommended 
tobacco-dependence treatments, Medicaid programs 
should inform their enrollees and providers about 
coverage changes, offer tobacco-dependence treat-
ments without barriers or limitations, measure treat-
ment usage rates, and assess any remaining barriers 
to coverage.
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or Zyban§ Group Individual
Alabama 2008 No No No No No No No No Yes (P)¶
Alaska 2006 Yes Yes Yes No Yes Yes Yes No Yes
Arizona 2008 Yes¶ Yes¶ Yes¶ Yes¶ Yes¶ Yes¶ Yes¶ No Yes (P)
Arkansas 1999 Yes Yes No No No Yes Yes No Yes
California 1996 Yes Yes Yes Yes Yes Yes Yes No No
Colorado 1996 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (P) Yes (P)
Delaware 1996 Yes Yes Yes Yes Yes Yes Yes No No
District of Columbia 1996 Yes Yes Yes Yes Yes Yes Yes No No
Florida** 1998 Yes (F) Yes (F) No No Yes (F)¶ Yes (F) Yes Yes (M) Yes (M)
Hawaii†† 1999 Yes Yes Yes Yes Yes Yes Yes No No
Idaho§§ 2007 Yes Yes Yes Yes Yes Yes Yes No No
Illinois 2000 Yes Yes Yes Yes Yes Yes Yes No No
Indiana 1999 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Iowa 2007 Yes Yes No No No Yes¶ Yes No Yes (F)¶
Kansas 1999 No Yes (F) No No No Yes (F) Yes (F) No No
Kentucky 2000 No No No No No No No Yes (P)(F) Yes (P)(F)
Louisiana 1990 Yes Yes Yes Yes No Yes Yes No No
Maine 1996 Yes Yes Yes Yes Yes Yes No¶¶ No Yes
Maryland 1996 No Yes Yes Yes No Yes Yes No Yes
Massachusetts 2006 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Michigan** 1997 Yes (F) Yes No No Yes (F) Yes (F) Yes (F) No Yes
Minnesota 1996 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Mississippi 2001 Yes Yes Yes Yes Yes Yes Yes Yes (P) Yes (P)
Montana 1996 Yes Yes Yes Yes Yes Yes Yes Yes¶ Yes¶
Nebraska 2008 Yes (F)¶ Yes (F)¶ No No No Yes (F)¶ Yes (F)¶ No Yes (F)¶
Nevada 1996 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) No No
New Hampshire 1996 Yes Yes Yes Yes Yes Yes Yes Yes (P) Yes***
New Jersey 1996 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) No No
New Mexico 1996 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes††† Yes (F)†††
New York 1999 Yes Yes Yes Yes No Yes Yes Yes (P)¶ No
North Carolina 1996 Yes Yes Yes Yes Yes Yes Yes No Yes¶
North Dakota 1996 Yes Yes No No Yes¶ Yes¶ Yes Yes Yes
Ohio 1998 Yes Yes Yes Yes Yes Yes Yes No No
Oklahoma 1999 Yes Yes Yes Yes Yes Yes Yes No Yes
Oregon§§§ 1998 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F)
Pennsylvania 2002 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Rhode Island 1994 Yes (M) Yes (M) Yes (M) Yes (M) Yes (M) No No Yes Yes
South Carolina 2004 Yes Yes Yes Yes Yes Yes Yes No No
South Dakota 2001 No No No No No Yes Yes No No
Texas 1996 Yes Yes Yes Yes No Yes Yes No No
Utah 2001 Yes Yes Yes Yes Yes Yes Yes Yes (P)(F) Yes (P)(F)
Vermont 1999 Yes Yes Yes Yes Yes Yes Yes No No
Virginia 1996 Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (F) Yes (P) Yes (P)¶
Washington 2008 Yes¶ Yes¶ No No No Yes (F)¶ Yes (P) No Yes (P)
West Virginia 2000 Yes Yes Yes Yes Yes No Yes Yes (M) Yes
Wisconsin 1996 Yes¶ Yes Yes Yes No Yes Yes No Yes
Wyoming 2007 Yes Yes No No Yes Yes Yes No*** Yes
Total states/areas 32 34 28 27 25 32 33 8 18
Fee-for-service only (F) 9 9 6 6 8 11 9 3 6
Managed-care organization only (M) 1 1 1 1 1 0 0 2 1
Pregnancy only (P) 0 0 0 0 0 0 1 7 8
Added since 2007 4 3 1 1 3 5 2 2 6
Abbreviations: F = coverage in Medicaid fee-for-service only; M = coverage in Medicaid managed-care organization only; P = Medicaid coverage exclusively for pregnant women. 
 * Based on response to the question “Does your state Medicaid program cover any of the following tobacco-dependence treatments?” Each state also was asked to provide documentation 
of coverage.
 † N = 47. In 2009, three states with Medicaid programs (Connecticut, Missouri, and Tennessee) covered none of the tobacco-dependence treatments recommended in the 2008 Public 
Health Service Clinical Practice Guideline. Georgia covers bupropion without prior authorization; therefore, it could be used for smoking cessation, although this was not the intention 
of the coverage policy.
 § Covered either bupropion or Zyban specifically for smoking cessation. 
 ¶ Treatment added since 2007 survey.
 ** Some of these treatments are required per managed-care organization contracts although plans have a choice of which treatments to cover.
 †† Hawaii previously covered tobacco-dependence treatments only after the gum or patch was used in conjunction with quitline support for 2 weeks. This policy was revised in June 2009 
and is no longer contingent on quitline enrollment.
 §§ Idaho provides an allowance of $200 per enrollee per year for personal health benefits that can be applied to smoking cessation benefits.
 ¶¶ Maine covers bupropion, but not specifically for smoking cessation.
 *** Response differs from the previous survey because of a reporting error. In most cases, this resulted from the state reporting on managed-care organization coverage policies and not 
Medicaid fee-for-service.
 ††† Fee-for-service covers when there is a valid behavioral health diagnosis other than tobacco dependence.
 §§§ Oregon requires that managed-care organizations cover “behavioral and tobacco cessation therapy products” but does not specify coverage of specific tobacco-dependence treatments; 
however, most managed-care organizations cover the same treatments covered under fee-for-service Medicaid.
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varies considerably for specific tobacco-dependence 
treatments within states and across states. Tobacco-
dependence treatments are one of the few clinical 
preventive services shown to reduce costs (7). Insurers 
that provide adequate access and support for per-
sons seeking to quit smoking can improve cessation 
rates substantially, with potential for considerable 
improvement in public health and reduction in 
medical expenditures (7,8). In Massachusetts, for 
example, a mandate for Medicaid coverage of tobacco-
dependence cessation treatments was associated with 
a 26% decline in smoking rates among Medicaid 
enrollees (9).
The findings in this report are subject to at least 
three limitations. First, Medicaid staff members 
self-report information on their Medicaid programs. 
Documentation to verify coverage policies was 
obtained for 94% of programs; where documentation 
was not available, errors might have occurred. Second, 
MCO contracts were not available from all programs. 
If the state informant did not possess a written contract 
or policy specifying that tobacco-dependence treat-
ments were covered, the response given by the respon-
dent was assumed to be accurate. Finally, many MCOs 
offer coverage for tobacco-dependence treatments to 
Medicaid enrollees, although it is not required per 
contracts with Medicaid. Consequently, reported data 
might underestimate tobacco-dependence treatment 
coverage among MCO enrollees.
Recent federal policy is increasing access to 
smoking cessation treatments. Section 4107 of the 
Affordable Care Act has required Medicaid programs 
to cover tobacco-dependence treatments for preg-
nant women, with no cost-sharing since October 1, 
2010 (5). Section 4106 of the act permits Medicaid 
programs to cover the A and B level recommenda-
tions of the U.S. Preventive Services Task Force, 
including cessation counseling and all Food and 
Drug Administration–approved tobacco-dependence 
treatments. States that offer such benefits and adult 
vaccination benefits, and prohibit cost sharing on 
these benefits, will receive a one full percentage point 
increase in the Medicaid federal medical assistance 
percentage for expenditures on these services, effective 
January 1, 2013 (3,5). Currently, only eight Medicaid 
programs cover all medications and at least one form 
of counseling for their entire population; the remain-
ing 43 Medicaid programs would need to add cover-
age for additional tobacco-dependence treatments if 
they seek to comply with the U.S. Preventive Services 
Task Force recommendations. Previous research 
indicates that knowledge of Medicaid coverage for 
tobacco-dependence treatments among Medicaid-
enrolled smokers is very low (10). To increase the 
impact of the federal legislation, it is important that 
Medicaid programs inform their enrollees and provid-
ers about changes in coverage for tobacco-dependence 
treatments and offer these treatments without barri-
ers or limitations. In addition, future monitoring of 
Medicaid programs should include measurement of 
usage rates of tobacco-dependence treatments and 
assessment of any existing barriers to coverage.
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World Stroke Day — October 29, 2010
October 29 is World Stroke Day 2010. Stroke is 
the third leading cause of death in the United States 
(1). Approximately 795,000 strokes occur annually 
in the United States, with an estimated cost of more 
than $73 billion (1). The theme for this year’s World 
Stroke Day is “One in Six,” to raise awareness that 
one in six persons worldwide will have a stroke in 
their lifetime, and that every 6 seconds, someone 
somewhere will die from a stroke (2,3).
This campaign stresses that the occurrence of 
stroke is common and widespread, but that stroke 
can be prevented and stroke survivors can recover and 
regain their quality of life with care and support. The 
campaign recommends the following six actions to 
reduce the likelihood of having a stroke:
•	 Know	 your	 personal	 risk	 factors,	 including	




of fresh fruits and vegetables.
•	 Limit	alcohol	consumption.
•	 Avoid	 cigarette	 smoke.	 People	 who	 smoke	
should seek help to stop now.
•	 Learn	to	recognize	the	warning	signs	of	a	stroke	
and call 9-1-1 right away if someone is suspected 
of having a stroke.
CDC addresses stroke prevention through state-
based programs to prevent heart disease and stroke, 
through the Paul Coverdell National Acute Stroke 
Registry, and through many other partnerships. 
Information about stroke and stroke prevention is 
available at http://www.cdc.gov/stroke, and additional 




1. Lloyd-Jones D, Adams R, Brown TM, et al. Heart disease and 
stroke statistics 2010 update. A report from the American 
Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Circulation 2010;121:e46–215.
2. Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk 
of stroke: estimates from the Framingham Study. Stroke 
2006;37:345–50.
3. World Health Organization. The atlas of heart disease and 
stroke. Geneva, Switzerland: World Health Organization; 
2004.
Menu of Suggested Provisions for State 
Tuberculosis Prevention and Control Laws 
Available Online
Tuberculosis (TB) laws provide authority for state 
and local TB programs to prevent and control TB, an 
airborne infectious disease that sickens approximately 
11,000–12,000 persons each year in the United 
States (1). CDC, in collaboration with the National 
Tuberculosis Controllers Association, has developed a 
Menu of Suggested Provisions for State Tuberculosis 
Prevention and Control Laws. A request by the 
Advisory Council for the Elimination of Tuberculosis 
for a model TB prevention and control act prompted 
development of the menu. 
The menu features a set of alternative provisions 
within each section for consideration by public health 
officials and their legal counsel in the enactment, 
promulgation, amendment, or implementation of 
laws to prevent and control TB. The menu is intended 
to serve as a practical resource for public health offi-
cials and their legal counsel in their efforts to eliminate 




1. CDC. Decrease in reported tuberculosis cases—United States, 
2009. MMWR 2010;59:289–94.
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QuickStats 
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Death Rates* For Persons Aged ≥65 Years, with Diabetes as the Underlying or a 
Contributing Cause, by Race and Sex — United States, 1981–2007
* Rates are age-adjusted per 100,000 U.S. standard population aged ≥65 years. Cause of death is based on 
International Classification of Diseases, Ninth Revision (ICD-9) code 250 (Diabetes mellitus) for 1981–1998 
and International Classification of Diseases, 10th Revision (ICD-10) codes E10–E14 (Diabetes mellitus) for 
1999–2007. 
Diabetes is a leading cause of death in the United States and a contributing cause of deaths from many other conditions. In 
2007, diabetes was a contributing cause of death 2.4 times as often as it was the underlying cause of death for persons aged 
≥65 years. Age-adjusted death rates for deaths with diabetes declined for white and black persons aged ≥65 years from 2005 
to 2007, after generally increasing from 1981 to 2002. In 2007, the rate was higher for black men and women than for white 
men and women. 
Sources: CDC. National Vital Statistics System. Available at http://www.cdc.gov/nchs/nvss.htm.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — — 1 — 1 1 —
Botulism, total 1 82 3 118 145 144 165 135
foodborne — 6 0 10 17 32 20 19
infant — 57 2 83 109 85 97 85
other (wound and unspecified) 1 19 0 25 19 27 48 31 OH (1)
Brucellosis — 97 2 115 80 131 121 120
Chancroid — 31 0 28 25 23 33 17
Cholera — 5 0 10 5 7 9 8
Cyclosporiasis§ 1 145 1 141 139 93 137 543 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
California serogroup virus disease — 53 1 55 62 55 67 80
Eastern equine encephalitis virus disease — 10 0 4 4 4 8 21
Powassan virus disease — 5 — 6 2 7 1 1
St. Louis encephalitis virus disease — 6 0 12 13 9 10 13
Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
serotype b — 13 1 35 30 22 29 9
nonserotype b 1 133 2 236 244 199 175 135 OH (1)
unknown serotype 2 181 2 178 163 180 179 217 NY (1), OK (1)
Hansen disease§ 1 35 2 103 80 101 66 87 CA (1)
Hantavirus pulmonary syndrome§ — 16 0 20 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 3 167 6 242 330 292 288 221 MD (1), TX (1), CA (1)
HIV infection, pediatric (age <13 yrs)†† — — 3 — — — — 380
Influenza-associated pediatric mortality§,§§ — 56 3 358 90 77 43 45
Listeriosis 9 616 22 851 759 808 884 896 VT (1), PA (2), OH (1), ND (1), VA (1), NC (1), FL (1), HI (1)
Measles¶¶ — 55 0 71 140 43 55 66
Meningococcal disease, invasive***:
A, C, Y, and W-135 — 188 5 301 330 325 318 297
serogroup B — 85 2 174 188 167 193 156
other serogroup — 7 0 23 38 35 32 27
unknown serogroup 7 301 9 482 616 550 651 765 NY (1), PA (1), OH (1), MI (1), KY (1), CA (2)
Mumps 14 2,419 18 1,991 454 800 6,584 314 NYC (5), TX (9)
Novel influenza A virus infections††† — 1 0 43,774 2 4 NN NN
Plague — 2 0 8 3 7 17 8
Poliomyelitis, paralytic — — 0 1 — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 4 0 9 8 12 21 16
Q fever, total§,§§§ 1 98 3 114 120 171 169 136
acute 1 74 1 94 106 — — — CA (1)
chronic — 24 0 20 14 — — —
Rabies, human — 1 0 4 2 1 3 2
Rubella¶¶¶ — 6 0 3 16 12 11 11
Rubella, congenital syndrome — — — 2 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ — 134 1 161 157 132 125 129
Syphilis, congenital (age <1 yr)†††† — 165 8 423 431 430 349 329
Tetanus — 6 1 18 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ 1 58 2 74 71 92 101 90 CA (1)
Trichinellosis — 3 0 13 39 5 15 16
Tularemia 1 82 2 93 123 137 95 154 CA (1)
Typhoid fever 4 315 9 397 449 434 353 324 NY (1), WA (2), CA (1)
Vancomycin-intermediate Staphylococcus aureus§ — 70 1 78 63 37 6 2
Vancomycin-resistant Staphylococcus aureus§ — 1 0 1 — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 9 634 11 789 588 549 NN NN MD (1), VA (1), NC (1), TN (1), TX (2), WA (1), CA (2)
Viral hemorrhagic fever§§§§ — 1 — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
Notifiable Diseases and Mortality Tables
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Notifiable Disease Data Team and 122 Cities Mortality Data Team
 Patsy A. Hall-Baker
Deborah A. Adams  Rosaline Dhara
Willie J. Anderson  Pearl C. Sharp
Michael S. Wodajo  Lenee Blanton
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 


























TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week 
ending October 16, 2010 (41st week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting year 2010 is provisional, whereas data for 2005 through 2009 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/ncphi/disss/nndss/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the domestic arboviral diseases, STD data, TB 
data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV.  Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 286 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 281 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. 
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. During 2009, four cases of human 
infection with novel influenza A viruses, different from the 2009 pandemic influenza A (H1N1) strain, were reported to CDC.  The one case of novel influenza A virus infection reported to 
CDC during 2010 was identified as swine influenza A (H3N2) virus and is unrelated to 2009 pandemic influenza A (H1N1) virus. Total case counts for 2009 were provided by the Influenza 
Division, National Center for Immunization and Respiratory Diseases (NCIRD).
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
 §§§§ There was one case of viral hemorrhagic fever reported during week 12. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 11,466 23,234 26,182 926,824 991,863 78 123 324 6,198 6,058
New England 506 739 1,396 30,738 31,583 1 8 72 368 393
Connecticut — 213 736 7,172 9,195 — 0 66 66 38
Maine† 20 50 75 1,996 1,898 1 1 7 68 44
Massachusetts 384 400 653 15,997 14,886 — 2 8 120 153
New Hampshire 50 41 115 1,903 1,714 — 1 5 44 69
Rhode Island† 22 65 120 2,687 2,939 — 0 2 10 21
Vermont† 30 23 51 983 951 — 1 9 60 68
Mid. Atlantic 1,658 3,292 4,619 132,724 124,691 8 15 37 659 687
New Jersey 431 483 691 20,113 19,404 — 0 1 — 46
New York (Upstate) 592 679 2,530 26,942 24,403 1 3 16 175 182
New York City 87 1,206 2,142 48,595 46,368 — 1 5 70 70
Pennsylvania 548 889 1,092 37,074 34,516 7 9 26 414 389
E.N. Central 849 3,508 4,127 135,036 160,149 13 29 116 1,673 1,432
Illinois 16 788 1,225 27,214 48,904 — 3 17 209 134
Indiana — 332 786 15,015 18,510 — 4 10 133 235
Michigan 601 897 1,420 37,854 36,881 4 5 17 270 231
Ohio 129 960 1,078 38,333 39,055 6 7 24 391 315
Wisconsin 103 415 502 16,620 16,799 3 9 55 670 517
W.N. Central 212 1,334 1,565 53,335 56,732 17 23 81 1,139 925
Iowa 9 186 265 7,822 7,743 — 4 22 281 179
Kansas 15 186 235 7,415 8,634 1 2 9 117 87
Minnesota — 274 331 10,695 11,586 — 0 18 98 271
Missouri 175 495 599 19,856 20,642 4 4 30 329 158
Nebraska† — 93 237 3,776 4,316 3 2 26 205 101
North Dakota — 34 89 1,375 1,422 9 0 18 28 11
South Dakota 13 61 77 2,396 2,389 — 2 6 81 118
S. Atlantic 3,394 4,484 5,681 178,943 200,947 12 19 51 825 925
Delaware 86 85 220 3,487 3,768 — 0 2 7 8
District of Columbia 95 93 177 3,904 5,524 — 0 1 2 6
Florida 653 1,407 1,694 59,115 58,894 4 7 23 307 370
Georgia 272 264 1,229 11,983 32,169 2 5 31 242 289
Maryland† 436 459 1,031 18,571 17,749 1 1 3 30 35
North Carolina 579 785 1,562 32,664 33,356 1 1 12 66 93
South Carolina† 824 523 694 21,663 21,751 1 1 8 76 49
Virginia† 377 596 902 24,594 24,817 3 2 8 80 62
West Virginia 72 70 137 2,962 2,919 — 0 3 15 13
E.S. Central 1,403 1,733 2,415 70,063 74,445 3 4 17 239 186
Alabama† 541 493 748 20,782 21,310 2 1 11 106 57
Kentucky 228 288 642 11,899 9,832 1 1 6 68 52
Mississippi 385 384 780 15,055 19,227 — 0 3 15 16
Tennessee† 249 571 728 22,327 24,076 — 1 5 50 61
W.S. Central 925 2,971 4,578 122,659 131,083 7 8 39 349 461
Arkansas† 279 250 392 9,381 11,673 1 1 3 30 46
Louisiana 389 228 1,076 10,974 23,075 — 1 5 48 46
Oklahoma 257 258 1,374 12,307 11,621 2 1 8 71 105
Texas† — 2,176 3,201 89,997 84,714 4 5 30 200 264
Mountain 733 1,519 1,904 59,573 63,051 6 10 28 451 482
Arizona 332 499 713 20,207 20,865 3 0 3 31 29
Colorado 170 372 617 14,143 15,101 2 2 8 111 123
Idaho† — 69 200 2,971 2,794 1 2 6 79 78
Montana† 12 60 76 2,377 2,413 — 1 4 40 49
Nevada† — 171 337 7,382 8,185 — 0 6 30 19
New Mexico† 173 170 453 6,166 7,212 — 2 10 93 128
Utah 34 116 175 4,780 4,921 — 1 4 54 36
Wyoming† 12 38 79 1,547 1,560 — 0 2 13 20
Pacific 1,786 3,623 5,350 143,753 149,182 11 12 28 495 567
Alaska — 110 148 4,608 4,217 — 0 1 3 6
California 1,332 2,766 4,406 110,661 114,127 4 7 19 282 336
Hawaii — 113 158 4,550 4,874 — 0 0 — 1
Oregon 139 208 468 8,745 8,621 2 3 13 141 159
Washington 315 387 497 15,189 17,343 5 2 8 69 65
Territories
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 5 31 232 302 — 0 0 — —
Puerto Rico 92 93 265 4,216 5,986 N 0 0 N N
U.S. Virgin Islands — 9 29 323 416 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Dengue Virus Infection
Reporting area
Dengue Fever† Dengue Hemorrhagic Fever§
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 5 29 346 NN — 0 1 4 NN
New England — 0 2 4 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine¶ — 0 2 3 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island¶ — 0 0 — NN — 0 0 — NN
Vermont¶ — 0 1 1 NN — 0 0 — NN
Mid. Atlantic — 0 9 74 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 7 62 NN — 0 0 — NN
Pennsylvania — 0 2 12 NN — 0 0 — NN
E.N. Central — 0 5 35 NN — 0 1 1 NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 2 10 NN — 0 0 — NN
Michigan — 0 2 8 NN — 0 0 — NN
Ohio — 0 2 12 NN — 0 0 — NN
Wisconsin — 0 2 5 NN — 0 1 1 NN
W.N. Central — 0 2 17 NN — 0 0 — NN
Iowa — 0 1 2 NN — 0 0 — NN
Kansas — 0 1 1 NN — 0 0 — NN
Minnesota — 0 2 13 NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska¶ — 0 0 — NN — 0 0 — NN
North Dakota — 0 1 1 NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 1 16 174 NN — 0 1 2 NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 1 14 150 NN — 0 1 2 NN
Georgia — 0 2 9 NN — 0 0 — NN
Maryland¶ — 0 0 — NN — 0 0 — NN
North Carolina — 0 1 4 NN — 0 0 — NN
South Carolina¶ — 0 3 9 NN — 0 0 — NN
Virginia¶ — 0 0 — NN — 0 0 — NN
West Virginia — 0 1 2 NN — 0 0 — NN
E.S. Central — 0 1 4 NN — 0 0 — NN
Alabama¶ — 0 1 1 NN — 0 0 — NN
Kentucky — 0 1 1 NN — 0 0 — NN
Mississippi — 0 1 1 NN — 0 0 — NN
Tennessee¶ — 0 1 1 NN — 0 0 — NN
W.S. Central — 0 1 4 NN — 0 1 1 NN
Arkansas¶ — 0 0 — NN — 0 1 1 NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 1 4 NN — 0 0 — NN
Texas¶ — 0 0 — NN — 0 0 — NN
Mountain — 0 2 13 NN — 0 0 — NN
Arizona — 0 1 4 NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho¶ — 0 1 2 NN — 0 0 — NN
Montana¶ — 0 1 2 NN — 0 0 — NN
Nevada¶ — 0 1 4 NN — 0 0 — NN
New Mexico¶ — 0 1 1 NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming¶ — 0 0 — NN — 0 0 — NN
Pacific — 0 5 21 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 5 11 NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 10 NN — 0 0 — NN
Territories
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 94 536 8,199 NN — 0 3 30 NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage, other clinical, and unknown case classifications. 
§ DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 3 10 181 514 821 4 11 309 616 779 — 2 35 90 155
New England — 0 3 3 43 3 2 8 64 227 — 0 2 7 2
Connecticut — 0 0 — — — 0 5 18 16 — 0 2 5 —
Maine§ — 0 1 2 3 — 0 2 14 12 — 0 0 — —
Massachusetts — 0 0 — 9 — 0 4 — 84 — 0 0 — —
New Hampshire — 0 1 1 4 — 0 3 11 16 — 0 1 2 1
Rhode Island§ — 0 2 — 26 3 0 7 21 99 — 0 0 — 1
Vermont§ — 0 0 — 1 — 0 0 — — — 0 0 — —
Mid. Atlantic — 1 15 41 161 — 3 17 166 266 — 0 2 4 44
New Jersey — 0 3 — 91 — 0 2 1 65 — 0 0 — —
New York (Upstate) — 0 15 24 44 — 2 17 162 192 — 0 1 4 6
New York City — 0 3 16 9 — 0 1 3 8 — 0 0 — 1
Pennsylvania — 0 5 1 17 — 0 1 — 1 — 0 1 — 37
E.N. Central — 0 4 28 82 — 2 36 306 258 — 1 6 55 66
Illinois — 0 2 12 33 — 0 1 2 6 — 0 2 4 3
Indiana — 0 0 — — — 0 0 — — — 0 3 28 36
Michigan — 0 1 2 5 — 0 0 — — — 0 1 3 —
Ohio — 0 3 6 12 — 0 1 2 1 — 0 0 — 2
Wisconsin — 0 1 8 32 — 2 36 302 251 — 0 3 20 25
W.N. Central — 1 13 114 146 — 0 261 9 7 — 0 30 11 16
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 1 6 6 — 0 0 — 1 — 0 0 — —
Minnesota — 0 6 — 1 — 0 261 — 3 — 0 30 — 3
Missouri — 1 13 106 137 — 0 3 9 2 — 0 3 11 13
Nebraska§ — 0 1 2 2 — 0 0 — 1 — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 3 4 19 225 232 — 1 7 52 15 — 0 1 6 2
Delaware — 0 3 17 19 — 0 1 4 2 — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 2 8 10 — 0 1 3 3 — 0 0 — —
Georgia — 0 4 19 17 — 0 1 1 1 — 0 1 1 —
Maryland§ 2 0 3 22 37 — 0 2 12 3 — 0 1 2 —
North Carolina — 1 13 91 59 — 0 4 19 3 — 0 0 — —
South Carolina§ — 0 2 3 10 — 0 1 1 — — 0 0 — —
Virginia§ 1 1 13 65 79 — 0 2 12 3 — 0 1 3 2
West Virginia — 0 0 — 1 — 0 0 — — — 0 1 — —
E.S. Central — 1 10 82 124 1 0 2 17 3 — 0 1 6 24
Alabama§ — 0 3 10 6 — 0 2 7 1 — 0 0 — —
Kentucky — 0 2 14 10 — 0 0 — — — 0 0 — —
Mississippi — 0 1 3 6 — 0 1 1 — — 0 0 — —
Tennessee§ — 1 6 55 102 1 0 2 9 2 — 0 1 6 24
W.S. Central — 0 141 20 30 — 0 23 2 1 — 0 1 1 —
Arkansas§ — 0 34 2 4 — 0 6 — — — 0 0 — —
Louisiana — 0 1 1 — — 0 0 — — — 0 0 — —
Oklahoma — 0 105 14 24 — 0 16 2 1 — 0 0 — —
Texas§ — 0 2 3 2 — 0 1 — — — 0 1 1 —
Mountain — 0 0 — — — 0 0 — — — 0 0 — 1
Arizona — 0 0 — — — 0 0 — — — 0 0 — 1
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 1 3 — 0 0 — 2 — 0 1 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Cumulative total E. ewingii cases reported for year 2010 = 10.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 233 346 666 14,003 15,022 2,933 5,446 6,325 215,513 242,009 17 59 171 2,272 2,294
New England 10 31 53 1,188 1,421 57 100 196 4,091 3,864 — 3 21 127 155
Connecticut — 5 13 236 242 — 43 169 1,706 1,847 — 0 15 28 42
Maine§ 8 3 12 172 180 — 3 11 136 110 — 0 2 10 17
Massachusetts — 12 20 463 610 39 45 81 1,851 1,519 — 2 8 65 75
New Hampshire — 3 9 118 169 4 3 7 119 83 — 0 2 9 10
Rhode Island§ — 1 7 49 52 14 5 13 232 269 — 0 1 8 7
Vermont§ 2 4 10 150 168 — 0 17 47 36 — 0 1 7 4
Mid. Atlantic 46 60 103 2,392 2,789 419 677 941 27,740 25,077 5 11 34 442 461
New Jersey — 5 13 207 357 116 101 161 4,330 3,800 — 2 7 73 105
New York (Upstate) 30 22 84 899 1,058 99 104 422 4,409 4,564 4 3 20 118 112
New York City 6 16 33 698 682 27 228 394 9,472 8,740 — 2 6 86 57
Pennsylvania 10 14 24 588 692 177 224 342 9,529 7,973 1 4 9 165 187
E.N. Central 29 52 78 2,279 2,384 231 935 1,260 36,850 51,185 3 10 20 392 361
Illinois — 12 24 469 514 8 183 380 6,266 16,288 — 3 9 118 135
Indiana — 5 13 191 239 — 91 218 4,228 5,977 — 1 6 69 65
Michigan 5 13 23 543 543 151 243 472 10,408 11,972 — 0 4 26 18
Ohio 23 16 24 677 666 40 316 372 12,301 12,774 3 2 6 95 82
Wisconsin 1 9 26 399 422 32 93 155 3,647 4,174 — 2 5 84 61
W.N. Central 21 25 165 1,156 1,296 77 275 357 10,863 11,994 2 3 24 132 133
Iowa 3 5 11 232 246 4 32 52 1,323 1,334 — 0 1 1 —
Kansas 2 4 10 177 126 1 37 83 1,510 2,065 — 0 2 12 13
Minnesota — 0 135 136 250 — 41 62 1,515 1,866 — 0 17 25 47
Missouri 9 8 25 340 423 72 125 172 5,222 5,246 1 1 6 66 46
Nebraska§ 2 4 9 178 140 — 22 50 895 1,099 1 0 2 18 21
North Dakota 5 0 8 25 20 — 2 11 94 101 — 0 4 10 6
South Dakota — 2 7 68 91 — 6 17 304 283 — 0 0 — —
S. Atlantic 61 75 143 3,012 2,913 1,033 1,275 1,651 51,660 60,167 4 14 27 609 625
Delaware — 0 5 25 22 16 18 48 796 772 — 0 1 5 3
District of Columbia — 1 4 28 57 21 37 65 1,478 2,160 — 0 1 2 4
Florida 43 39 87 1,715 1,527 215 378 479 15,941 17,017 3 3 9 148 187
Georgia — 11 51 485 594 101 96 421 4,123 10,929 — 3 9 139 123
Maryland§ 3 5 11 210 226 135 132 237 5,346 4,845 1 1 6 54 75
North Carolina N 0 0 N N 201 258 596 10,936 11,356 — 2 9 105 76
South Carolina§ 2 2 9 119 86 239 152 233 6,554 6,805 — 2 7 69 60
Virginia§ 13 9 36 397 361 93 161 271 6,076 5,875 — 2 4 67 71
West Virginia — 1 5 33 40 12 9 20 410 408 — 0 5 20 26
E.S. Central — 5 15 198 337 405 479 698 19,005 21,469 — 3 12 138 139
Alabama§ — 4 8 145 162 139 145 217 6,002 6,080 — 0 3 21 34
Kentucky N 0 0 N N 78 76 156 3,098 2,874 — 0 2 27 19
Mississippi N 0 0 N N 118 109 216 4,249 6,000 — 0 2 10 7
Tennessee§ — 1 10 53 175 70 147 196 5,656 6,515 — 2 10 80 79
W.S. Central 3 8 16 296 413 262 795 1,236 33,115 38,373 2 2 20 103 98
Arkansas§ 2 2 9 102 115 102 74 133 2,885 3,606 — 0 3 14 15
Louisiana 1 3 9 131 168 71 68 441 3,169 7,516 — 0 3 18 17
Oklahoma — 2 7 63 130 89 79 359 3,615 3,683 2 1 15 63 62
Texas§ N 0 0 N N — 570 963 23,446 23,568 — 0 2 8 4
Mountain 18 30 50 1,283 1,346 86 181 262 7,091 7,449 1 5 15 234 202
Arizona — 3 8 126 166 47 63 109 2,381 2,476 — 2 10 89 65
Colorado 13 13 27 551 396 16 53 94 2,105 2,245 1 1 5 66 59
Idaho§ 4 4 9 169 162 — 2 6 87 81 — 0 2 13 3
Montana§ 1 2 7 83 113 — 2 6 86 64 — 0 1 2 1
Nevada§ — 1 11 78 95 — 28 94 1,313 1,435 — 0 2 6 16
New Mexico§ — 2 5 73 105 23 19 41 837 849 — 1 5 34 27
Utah — 4 12 171 254 — 6 15 254 242 — 0 4 18 28
Wyoming§ — 1 5 32 55 — 1 4 28 57 — 0 2 6 3
Pacific 45 53 133 2,199 2,123 363 594 810 25,098 22,431 — 2 9 95 120
Alaska — 2 6 78 95 — 23 37 991 771 — 0 2 19 15
California 24 33 61 1,370 1,384 305 485 692 20,718 18,484 — 0 4 12 39
Hawaii 1 0 4 25 18 — 14 25 581 506 — 0 2 7 27
Oregon 2 9 23 393 329 8 19 43 779 835 — 1 5 53 36
Washington 18 8 75 333 297 50 50 69 2,029 1,835 — 0 4 4 3
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 2 3 — 0 4 28 19 — 0 0 — —
Puerto Rico — 1 8 57 137 9 5 14 227 195 — 0 1 1 4
U.S. Virgin Islands — 0 0 — — — 2 7 78 100 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 21 30 69 1,191 1,598 31 60 204 2,418 2,592 5 15 44 635 582
New England — 2 5 75 93 — 1 5 42 45 — 1 3 29 53
Connecticut — 0 3 23 18 — 0 2 15 13 — 0 3 19 41
Maine† — 0 1 7 1 — 0 2 11 11 — 0 1 — 1
Massachusetts — 1 4 36 58 — 0 2 8 17 — 0 1 9 10
New Hampshire — 0 1 1 7 — 0 2 6 4 N 0 0 N N
Rhode Island† — 0 4 8 7 U 0 0 U U U 0 0 U U
Vermont† — 0 0 — 2 — 0 1 2 — — 0 1 1 1
Mid. Atlantic 3 4 8 157 229 2 5 10 227 274 — 2 6 83 80
New Jersey — 0 3 11 59 — 1 5 54 83 — 0 2 10 5
New York (Upstate) 3 1 4 51 39 2 1 6 41 46 — 1 4 48 37
New York City — 1 4 53 72 — 2 4 71 56 — 0 0 — 5
Pennsylvania — 1 4 42 59 — 1 5 61 89 — 0 3 25 33
E.N. Central 2 4 8 168 243 — 9 17 369 353 — 2 9 103 72
Illinois — 1 3 39 112 — 2 6 65 97 — 0 1 1 4
Indiana — 0 2 15 16 — 1 5 47 57 — 0 2 21 15
Michigan 1 1 4 50 56 — 3 6 99 107 — 1 6 65 26
Ohio 1 0 5 40 34 — 2 6 80 73 — 0 1 9 24
Wisconsin — 0 3 24 25 — 1 8 78 19 — 0 2 7 3
W.N. Central — 1 13 64 94 2 2 15 94 114 — 0 11 16 17
Iowa — 0 3 6 32 — 0 2 12 28 — 0 1 — 9
Kansas — 0 3 11 7 — 0 2 6 6 — 0 1 1 1
Minnesota — 0 12 14 15 — 0 13 7 20 — 0 9 6 3
Missouri — 0 2 20 19 2 1 3 56 38 — 0 1 6 —
Nebraska† — 0 4 12 18 — 0 2 12 19 — 0 1 3 2
North Dakota — 0 1 — — — 0 0 — — — 0 1 — 1
South Dakota — 0 1 1 3 — 0 1 1 3 — 0 0 — 1
S. Atlantic 5 8 14 284 342 13 16 40 701 713 1 4 8 135 133
Delaware — 0 1 7 3 — 0 2 20 25 U 0 0 U U
District of Columbia — 0 1 1 1 — 0 1 3 10 — 0 1 2 1
Florida 4 3 7 113 146 7 6 12 244 231 — 1 6 44 35
Georgia — 1 3 33 38 2 3 7 118 122 — 0 2 7 30
Maryland† — 0 4 22 39 1 1 6 52 61 — 0 2 20 19
North Carolina 1 0 5 44 34 1 1 16 82 93 1 0 3 36 20
South Carolina† — 1 3 22 50 2 1 4 47 43 — 0 1 1 1
Virginia† — 1 6 40 28 — 1 14 76 74 — 0 2 11 8
West Virginia — 0 2 2 3 — 0 14 59 54 — 0 5 14 19
E.S. Central — 1 3 33 34 3 7 13 279 268 2 3 7 118 81
Alabama† — 0 1 6 9 2 1 5 56 73 — 0 1 5 7
Kentucky — 0 2 13 8 1 2 8 99 64 — 2 5 81 48
Mississippi — 0 1 2 8 — 1 3 27 26 U 0 0 U U
Tennessee† — 0 2 12 9 — 2 8 97 105 2 1 4 32 26
W.S. Central 4 2 19 102 160 5 9 109 373 454 2 1 14 58 45
Arkansas† — 0 3 — 7 — 0 4 32 54 — 0 1 — 2
Louisiana — 0 2 7 5 — 1 4 40 56 — 0 1 5 7
Oklahoma — 0 3 — 3 2 2 19 76 79 2 0 12 23 12
Texas† 4 2 18 95 145 3 5 87 225 265 — 1 3 30 24
Mountain 1 3 8 118 136 — 2 8 94 113 — 1 5 41 40
Arizona — 1 5 56 58 — 0 2 23 38 U 0 0 U U
Colorado 1 1 3 26 44 — 0 3 21 22 — 0 2 7 24
Idaho† — 0 2 6 4 — 0 1 6 11 — 0 2 9 4
Montana† — 0 1 4 6 — 0 1 1 1 — 0 0 — 1
Nevada† — 0 2 12 10 — 0 3 33 27 — 0 1 4 3
New Mexico† — 0 1 3 7 — 0 1 4 6 — 0 2 11 5
Utah — 0 1 8 5 — 0 1 5 4 — 0 2 10 3
Wyoming† — 0 3 3 2 — 0 1 1 4 — 0 0 — —
Pacific 6 5 16 190 267 6 6 20 239 258 — 1 6 52 61
Alaska — 0 1 1 2 — 0 1 3 2 U 0 2 U U
California 5 4 15 153 211 4 4 17 162 185 — 0 4 21 32
Hawaii — 0 2 3 8 — 0 1 1 5 U 0 0 U U
Oregon — 0 2 17 13 — 1 4 34 32 — 0 3 13 15
Washington 1 0 2 16 33 2 1 4 39 34 — 0 6 18 14
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 6 16 4 — 1 6 35 50 — 0 6 28 42
Puerto Rico — 0 1 12 21 — 0 2 16 28 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 46 57 112 2,402 2,759 249 418 2,336 21,637 32,306 21 26 89 1,122 1,130
New England — 3 13 153 170 27 121 423 6,060 11,155 — 1 4 54 53
Connecticut — 0 4 32 47 5 42 200 2,218 3,770 — 0 1 1 5
Maine† — 0 2 9 7 20 12 76 598 743 — 0 1 5 2
Massachusetts — 1 7 77 84 — 36 161 1,876 4,841 — 1 3 37 34
New Hampshire — 0 5 15 11 — 22 63 996 1,235 — 0 1 3 4
Rhode Island† — 0 3 11 14 1 1 35 101 214 — 0 1 5 5
Vermont† — 0 2 9 7 1 4 26 271 352 — 0 1 3 3
Mid. Atlantic 18 15 31 619 998 90 175 694 10,357 14,068 2 7 17 306 330
New Jersey — 2 8 52 180 — 44 195 2,631 4,564 — 0 4 1 86
New York (Upstate) 10 5 19 217 295 66 53 577 2,466 3,391 1 1 6 63 40
New York City — 2 8 108 203 — 2 18 58 937 — 4 14 197 159
Pennsylvania 8 6 16 242 320 24 74 373 5,202 5,176 1 1 3 45 45
E.N. Central 8 11 40 573 593 2 18 161 1,614 2,752 2 2 9 123 148
Illinois — 1 15 118 105 — 1 16 104 134 — 1 7 44 62
Indiana 1 2 6 87 52 — 1 7 64 78 — 0 2 7 20
Michigan 3 3 19 136 131 2 1 14 90 94 — 0 4 26 25
Ohio 4 4 12 186 236 — 0 5 21 45 2 0 5 37 32
Wisconsin — 1 11 46 69 — 16 136 1,335 2,401 — 0 1 9 9
W.N. Central 7 2 19 99 97 3 3 1,395 108 200 1 1 11 60 56
Iowa — 0 2 13 20 — 1 10 75 103 — 0 2 9 10
Kansas — 0 2 8 7 — 0 1 6 18 — 0 2 10 6
Minnesota 4 0 16 27 8 — 0 1,380 — 71 — 0 11 3 23
Missouri 2 0 4 30 49 — 0 1 1 3 1 0 3 20 10
Nebraska† — 0 2 8 11 — 0 2 9 4 — 0 2 15 6
North Dakota 1 0 1 6 1 3 0 15 16 — — 0 1 — —
South Dakota — 0 2 7 1 — 0 1 1 1 — 0 2 3 1
S. Atlantic 6 10 26 414 442 123 60 169 3,172 3,744 15 6 35 296 298
Delaware — 0 3 13 17 2 11 31 538 864 — 0 1 2 4
District of Columbia — 0 4 13 18 — 0 4 19 57 — 0 2 8 15
Florida 2 3 9 141 136 1 2 11 84 76 1 2 7 106 80
Georgia — 1 4 37 46 — 0 2 8 38 — 0 2 3 61
Maryland† 4 2 12 91 115 95 25 74 1,383 1,785 6 1 18 70 61
North Carolina — 0 7 47 48 2 1 9 75 89 5 0 13 45 24
South Carolina† — 0 2 9 9 — 0 3 27 32 1 0 1 4 4
Virginia† — 1 6 52 46 17 15 79 933 671 2 1 5 55 47
West Virginia — 0 3 11 7 6 0 32 105 132 — 0 2 3 2
E.S. Central 2 2 10 103 114 — 1 4 39 31 — 0 3 26 29
Alabama† — 0 2 14 14 — 0 1 2 2 — 0 1 6 8
Kentucky — 0 4 22 43 — 0 1 4 1 — 0 3 6 9
Mississippi — 0 3 9 4 — 0 0 — — — 0 2 2 3
Tennessee† 2 1 6 58 53 — 1 4 33 28 — 0 2 12 9
W.S. Central 1 3 14 109 90 1 2 44 82 174 — 1 31 69 56
Arkansas† — 0 2 12 7 — 0 0 — — — 0 1 2 5
Louisiana — 0 3 7 10 — 0 1 2 — — 0 1 3 5
Oklahoma — 0 4 11 3 — 0 2 — — — 0 1 5 1
Texas† 1 2 10 79 70 1 2 42 80 174 — 1 30 59 45
Mountain — 3 10 124 112 — 0 3 19 50 — 1 3 49 43
Arizona — 1 5 43 36 — 0 1 3 5 — 0 2 22 8
Colorado — 0 5 27 19 — 0 1 2 1 — 0 2 15 24
Idaho† — 0 1 5 5 — 0 2 6 14 — 0 1 2 2
Montana† — 0 1 4 5 — 0 1 1 3 — 0 1 2 5
Nevada† — 0 2 18 12 — 0 1 — 12 — 0 1 4 —
New Mexico† — 0 2 6 9 — 0 2 5 5 — 0 1 1 —
Utah — 0 3 16 22 — 0 1 2 8 — 0 1 3 4
Wyoming† — 0 2 5 4 — 0 1 — 2 — 0 0 — —
Pacific 4 5 19 208 143 3 4 11 186 132 1 3 19 139 117
Alaska — 0 2 2 1 — 0 1 6 5 — 0 1 2 2
California 2 4 19 177 108 3 3 10 125 84 1 2 13 98 86
Hawaii — 0 1 1 1 N 0 0 N N — 0 1 1 1
Oregon — 0 3 11 14 — 1 4 46 33 — 0 1 9 11
Washington 2 0 4 17 19 — 0 3 9 10 — 0 5 29 17
Territories
American Samoa — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 1 — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — 1 N 0 0 N N — 0 2 4 5
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 7 16 43 581 742 317 300 1,756 14,429 12,478 27 69 145 2,753 4,314
New England — 0 2 13 27 — 8 20 339 545 3 4 15 185 281
Connecticut — 0 2 2 3 — 1 8 92 44 — 0 14 59 126
Maine§ — 0 1 3 4 — 0 5 36 76 2 1 4 52 46
Massachusetts — 0 1 3 12 — 4 11 164 310 — 0 0 — —
New Hampshire — 0 0 — 3 — 0 3 14 68 — 0 5 12 27
Rhode Island§ — 0 0 — 4 — 0 8 22 36 — 0 2 17 36
Vermont§ — 0 1 5 1 — 0 4 11 11 1 1 5 45 46
Mid. Atlantic 2 1 4 49 82 32 22 64 1,137 970 11 18 41 845 493
New Jersey — 0 2 9 15 — 3 8 99 199 — 0 0 — —
New York (Upstate) 1 0 3 10 17 5 8 27 401 174 11 8 19 423 376
New York City — 0 2 14 14 5 0 9 71 79 — 1 12 112 17
Pennsylvania 1 0 2 16 36 22 9 39 566 518 — 5 24 310 100
E.N. Central 2 2 8 105 134 54 74 173 3,612 2,620 3 2 38 266 211
Illinois — 0 4 19 34 — 12 29 574 556 — 1 22 160 79
Indiana — 0 3 22 28 — 9 26 429 298 — 0 0 — 25
Michigan 1 0 2 17 18 11 22 51 1,022 706 3 1 5 63 63
Ohio 1 1 2 27 34 43 22 69 1,245 911 — 0 12 43 44
Wisconsin — 0 2 20 20 — 6 17 342 149 — 0 0 — —
W.N. Central — 1 6 41 61 156 27 627 1,691 1,800 4 4 16 206 335
Iowa — 0 3 9 8 — 6 25 359 195 — 0 2 7 30
Kansas — 0 2 6 11 — 3 9 129 208 — 1 4 54 67
Minnesota — 0 2 2 11 143 0 601 682 366 — 0 9 26 51
Missouri — 0 3 17 21 5 8 25 291 855 — 1 6 62 62
Nebraska§ — 0 2 5 7 5 2 13 163 123 1 1 4 44 73
North Dakota — 0 1 2 1 3 0 30 41 17 3 0 7 13 4
South Dakota — 0 2 — 2 — 1 5 26 36 — 0 2 — 48
S. Atlantic — 3 7 110 139 11 27 77 1,212 1,373 5 22 73 875 1,783
Delaware — 0 1 2 2 — 0 4 10 12 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 4 6 — 0 0 — —
Florida — 1 5 50 45 7 5 28 258 454 — 0 60 72 161
Georgia — 0 2 9 28 — 3 18 185 205 — 0 13 — 337
Maryland§ — 0 1 6 9 1 2 8 95 120 — 6 14 297 327
North Carolina — 0 2 14 27 — 1 32 124 166 — 0 11 — 414
South Carolina§ — 0 1 10 11 3 5 19 292 216 — 0 0 — —
Virginia§ — 0 2 17 12 — 5 15 176 167 5 10 25 448 449
West Virginia — 0 2 2 5 — 1 13 68 27 — 1 6 58 95
E.S. Central 1 1 4 34 25 2 14 32 589 671 — 3 7 126 126
Alabama§ — 0 2 6 7 — 4 8 154 263 — 0 4 41 —
Kentucky 1 0 2 16 4 — 4 13 208 196 — 0 4 16 43
Mississippi — 0 1 3 3 — 1 6 53 56 — 0 1 1 4
Tennessee§ — 0 2 9 11 2 4 11 174 156 — 1 4 68 79
W.S. Central — 1 9 65 68 17 57 753 2,249 2,619 — 1 30 61 772
Arkansas§ — 0 2 5 6 — 3 29 119 291 — 0 7 21 38
Louisiana — 0 4 12 13 — 1 4 29 134 — 0 0 — —
Oklahoma — 0 7 15 10 1 0 41 54 41 — 0 30 40 30
Texas§ — 1 7 33 39 16 49 681 2,047 2,153 — 0 26 — 704
Mountain — 1 6 45 54 16 22 46 1,008 795 — 1 8 66 94
Arizona — 0 2 11 12 1 7 14 317 200 — 0 5 — —
Colorado — 0 4 14 18 11 4 15 182 188 — 0 0 — —
Idaho§ — 0 2 7 6 4 3 19 170 68 — 0 2 11 8
Montana§ — 0 1 1 5 — 1 12 62 48 — 0 3 16 25
Nevada§ — 0 1 8 4 — 0 7 29 23 — 0 1 5 6
New Mexico§ — 0 1 3 3 — 2 9 84 59 — 0 3 11 22
Utah — 0 1 1 2 — 3 10 154 187 — 0 1 2 12
Wyoming§ — 0 1 — 4 — 0 2 10 22 — 0 4 21 21
Pacific 2 3 16 119 152 29 35 189 2,592 1,085 1 3 12 123 219
Alaska — 0 1 1 6 — 0 6 35 38 — 0 2 12 11
California 2 2 13 79 99 8 25 166 1,912 545 1 2 12 100 197
Hawaii — 0 1 1 5 — 0 6 38 37 — 0 0 — —
Oregon — 1 3 25 29 1 6 16 279 230 — 0 2 11 11
Washington — 0 7 13 13 20 4 38 328 235 — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 2 — — — 0 0 — —
Puerto Rico — 0 1 — — — 0 1 2 1 — 1 3 36 34
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 854 924 1,680 39,159 38,756 76 78 206 3,656 3,770 152 268 527 10,769 12,717
New England 3 29 423 1,756 1,904 1 2 51 161 226 — 4 59 256 299
Connecticut — 0 407 407 430 — 0 51 51 67 — 0 53 53 43
Maine§ 3 2 7 100 111 1 0 3 16 16 — 0 1 5 5
Massachusetts — 21 48 945 953 — 1 8 62 86 — 4 16 179 207
New Hampshire — 3 10 138 233 — 0 2 17 32 — 0 2 9 18
Rhode Island§ — 2 17 109 121 — 0 26 2 1 — 0 3 9 21
Vermont§ — 1 5 57 56 — 0 2 13 24 — 0 1 1 5
Mid. Atlantic 51 96 217 4,637 4,559 6 8 31 423 366 7 34 53 1,301 2,385
New Jersey — 18 56 833 963 — 1 4 51 89 — 6 16 257 523
New York (Upstate) 32 24 78 1,193 1,079 5 3 15 164 123 2 4 19 182 180
New York City 2 25 56 1,112 1,048 — 1 7 62 53 2 6 13 244 376
Pennsylvania 17 29 82 1,499 1,469 1 3 13 146 101 3 16 35 618 1,306
E.N. Central 38 80 236 4,213 4,349 3 11 39 608 633 5 26 238 1,418 2,216
Illinois — 27 113 1,455 1,240 — 1 8 90 155 — 9 228 701 518
Indiana — 9 53 369 510 — 1 8 61 78 — 1 5 31 62
Michigan 3 15 45 753 823 — 2 16 144 119 — 4 9 194 192
Ohio 35 24 47 1,106 1,200 3 2 11 122 111 5 6 23 253 987
Wisconsin — 10 44 530 576 — 3 17 191 170 — 4 21 239 457
W.N. Central 40 44 99 2,007 2,219 8 10 39 525 646 21 48 88 1,788 813
Iowa 1 8 35 431 345 — 2 16 139 140 — 1 5 47 47
Kansas 4 7 18 360 333 1 1 6 56 50 2 5 14 210 167
Minnesota — 0 32 178 475 — 0 14 31 185 — 0 5 14 67
Missouri 13 12 44 673 542 4 3 27 209 120 11 42 75 1,472 497
Nebraska§ 9 4 13 200 299 2 1 6 64 80 8 1 4 38 27
North Dakota 13 0 39 46 59 — 0 7 — 7 — 0 5 — 4
South Dakota — 3 8 119 166 1 0 4 26 64 — 0 2 7 4
S. Atlantic 459 267 573 11,706 10,968 17 13 30 558 547 59 41 96 1,987 1,961
Delaware — 3 11 147 115 — 0 2 5 12 — 1 10 37 104
District of Columbia — 1 6 58 82 — 0 1 5 2 — 0 4 21 21
Florida 219 127 227 4,867 4,831 4 4 13 189 135 36 13 54 863 373
Georgia 50 40 129 2,069 1,950 — 1 15 86 56 9 13 38 597 531
Maryland§ 12 15 52 826 659 5 1 6 75 77 3 3 8 107 329
North Carolina 106 29 145 1,449 1,493 7 1 7 58 95 8 2 18 158 336
South Carolina§ 45 20 90 1,240 800 — 0 3 19 27 — 1 5 59 99
Virginia§ 27 18 68 903 860 1 2 15 105 119 3 3 15 119 162
West Virginia — 3 16 147 178 — 0 4 16 24 — 0 11 26 6
E.S. Central 22 52 174 2,862 2,543 — 4 11 191 179 3 11 40 528 674
Alabama§ 4 14 45 657 731 — 0 4 36 40 — 3 10 115 125
Kentucky 6 8 31 458 381 — 1 6 50 61 2 4 28 192 176
Mississippi 1 14 68 926 779 — 0 2 13 6 — 1 4 38 42
Tennessee§ 11 14 53 821 652 — 2 7 92 72 1 4 11 183 331
W.S. Central 125 114 547 4,719 4,565 7 5 68 241 250 41 50 251 1,968 2,384
Arkansas§ 10 10 43 606 521 1 1 5 44 35 — 1 9 51 262
Louisiana 1 21 47 940 945 — 0 2 14 20 — 4 13 199 154
Oklahoma 17 10 46 531 522 1 0 27 21 29 2 6 96 227 234
Texas§ 97 74 477 2,642 2,577 5 4 41 162 166 39 35 144 1,491 1,734
Mountain 14 49 105 2,174 2,496 6 9 33 463 495 3 15 32 623 981
Arizona 4 18 42 754 848 — 1 5 55 53 — 8 18 331 707
Colorado 9 10 23 463 529 2 2 18 154 150 3 2 6 98 82
Idaho§ — 3 9 127 151 4 1 7 77 82 — 0 3 22 7
Montana§ 1 2 7 75 95 — 1 5 36 32 — 0 1 6 11
Nevada§ — 4 22 237 218 — 0 5 28 31 — 0 6 34 65
New Mexico§ — 5 15 233 310 — 1 5 33 33 — 2 9 98 91
Utah — 5 17 248 267 — 1 7 66 101 — 0 4 34 16
Wyoming§ — 1 9 37 78 — 0 2 14 13 — 0 2 — 2
Pacific 102 115 299 5,085 5,153 28 9 46 486 428 13 21 64 900 1,004
Alaska — 1 5 69 55 — 0 1 2 1 — 0 2 1 2
California 59 84 227 3,843 3,858 8 5 35 213 203 12 16 51 742 809
Hawaii 5 4 14 159 279 — 0 4 18 7 1 0 3 17 35
Oregon — 8 48 427 357 2 1 7 78 67 — 1 4 47 43
Washington 38 14 61 587 604 18 3 18 175 150 — 1 22 93 115
Territories
American Samoa — 1 1 2 — — 0 0 — — — 1 1 2 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 1 4 11 — 0 0 — — — 0 3 1 10
Puerto Rico 1 10 39 423 462 — 0 0 — — — 0 1 4 11
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 2 2 12 139 134 28 17 421 1,254 1,163
New England — 0 0 — 2 — 0 1 3 9
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 1 2 4
Massachusetts — 0 0 — 1 — 0 1 — 5
New Hampshire — 0 0 — — — 0 1 1 —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 0 — 1 — 0 0 — —
Mid. Atlantic — 0 2 16 11 1 1 4 50 89
New Jersey — 0 0 — 2 — 0 2 — 57
New York (Upstate) — 0 1 2 — 1 0 3 15 13
New York City — 0 1 1 1 — 0 4 23 6
Pennsylvania — 0 2 13 8 — 0 1 12 13
E.N. Central — 0 1 4 9 1 1 9 87 79
Illinois — 0 1 2 1 — 0 5 28 47
Indiana — 0 1 2 3 1 0 5 43 10
Michigan — 0 0 — 4 — 0 1 1 1
Ohio — 0 0 — — — 0 2 14 17
Wisconsin — 0 0 — 1 — 0 1 1 4
W.N. Central — 0 5 18 18 1 3 21 274 246
Iowa — 0 0 — 1 — 0 1 4 4
Kansas — 0 1 2 1 — 0 0 — —
Minnesota — 0 1 — 1 — 0 1 — 1
Missouri — 0 5 14 7 1 3 20 266 237
Nebraska§ — 0 1 2 8 — 0 1 3 4
North Dakota — 0 0 — — — 0 1 1 —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic — 1 9 67 62 6 7 60 426 348
Delaware — 0 1 1 — — 0 3 17 16
District of Columbia — 0 0 — — — 0 1 — —
Florida — 0 1 3 — 1 0 2 11 5
Georgia — 0 6 45 48 — 0 0 — —
Maryland§ — 0 1 2 3 1 0 4 42 34
North Carolina — 0 3 11 7 3 1 48 228 229
South Carolina§ — 0 1 1 3 — 0 2 15 15
Virginia§ — 0 2 4 1 1 1 11 113 47
West Virginia — 0 0 — — — 0 0 — 2
E.S. Central — 0 3 20 9 1 4 29 329 243
Alabama§ — 0 1 4 3 — 1 8 68 59
Kentucky — 0 2 6 1 — 0 0 — —
Mississippi — 0 0 — — — 0 2 9 9
Tennessee§ — 0 3 10 5 1 3 20 252 175
W.S. Central 2 0 3 6 8 18 1 408 78 125
Arkansas§ 2 0 1 2 — 17 0 110 37 62
Louisiana — 0 0 — — — 0 1 2 2
Oklahoma — 0 3 3 6 — 0 287 22 43
Texas§ — 0 1 1 2 1 0 11 17 18
Mountain — 0 1 2 14 — 0 2 7 24
Arizona — 0 1 — 8 — 0 1 1 12
Colorado — 0 0 — 1 — 0 1 1 —
Idaho§ — 0 0 — — — 0 1 2 1
Montana§ — 0 1 2 4 — 0 1 1 6
Nevada§ — 0 0 — — — 0 0 — 1
New Mexico§ — 0 0 — — — 0 1 1 1
Utah — 0 0 — — — 0 1 1 1
Wyoming§ — 0 0 — 1 — 0 0 — 2
Pacific — 0 2 6 1 — 0 0 — —
Alaska N 0 0 N N N 0 0 N N
California — 0 2 5 1 — 0 0 — —
Hawaii N 0 0 N N N 0 0 N N
Oregon — 0 1 1 — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
Territories
American Samoa N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 123 199 495 11,071 2,339 15 51 156 1,722 1,831 98 240 413 9,495 11,173
New England 1 8 99 599 44 — 1 24 78 60 2 8 22 352 250
Connecticut — 0 92 265 — — 0 22 25 — — 1 10 69 45
Maine§ 1 2 6 95 14 — 0 1 8 7 — 0 3 23 2
Massachusetts — 0 5 54 3 — 1 4 37 37 — 5 15 211 180
New Hampshire — 0 7 59 — — 0 1 3 10 — 0 2 17 13
Rhode Island§ — 0 35 64 15 — 0 2 2 2 2 0 4 30 10
Vermont§ — 1 6 62 12 — 0 1 3 4 — 0 2 2 —
Mid. Atlantic 7 20 54 970 152 4 7 48 271 229 25 33 45 1,351 1,419
New Jersey — 1 8 83 — — 1 5 43 45 2 4 12 187 179
New York (Upstate) 1 3 12 128 61 1 3 19 91 99 1 2 11 104 95
New York City 4 6 25 379 10 3 1 24 94 71 17 18 31 770 873
Pennsylvania 2 7 22 380 81 — 0 5 43 14 5 7 16 290 272
E.N. Central 32 34 98 2,242 525 4 8 18 285 305 1 27 46 1,048 1,229
Illinois — 1 7 76 — — 2 5 69 50 — 9 23 334 597
Indiana — 7 24 439 202 — 1 6 38 62 — 3 13 139 125
Michigan 4 10 27 533 24 1 2 6 66 57 — 4 12 170 192
Ohio 24 15 49 919 299 3 2 6 79 102 1 9 18 370 276
Wisconsin 4 5 22 275 — — 1 4 33 34 — 1 3 35 39
W.N. Central 12 8 182 626 152 1 2 12 112 149 3 5 19 254 253
Iowa — 0 0 — — — 0 0 — — — 0 2 10 21
Kansas — 1 7 77 50 — 0 2 13 16 — 0 3 16 27
Minnesota — 0 179 287 38 — 0 10 44 70 — 1 9 97 60
Missouri 1 2 10 91 53 1 1 3 33 40 3 3 10 122 137
Nebraska§ 5 1 7 106 2 — 0 2 13 10 — 0 2 7 5
North Dakota 6 0 11 50 7 — 0 1 2 4 — 0 1 — 3
South Dakota — 0 3 15 2 — 0 2 7 9 — 0 1 2 —
S. Atlantic 27 49 144 2,600 1,056 3 12 28 432 437 27 54 218 2,224 2,677
Delaware 1 0 3 29 18 — 0 0 — 3 — 0 2 4 25
District of Columbia — 0 4 21 18 — 0 2 7 4 12 2 8 118 147
Florida 14 22 89 1,172 615 2 3 18 158 155 2 20 44 830 836
Georgia 2 10 28 427 314 1 3 12 120 118 1 9 167 394 624
Maryland§ 2 7 31 409 4 — 1 6 44 65 5 6 12 240 239
North Carolina — 0 0 — — — 0 0 — — — 7 31 286 448
South Carolina§ 8 6 25 403 — — 1 4 42 38 7 2 7 117 98
Virginia§ — 0 4 46 — — 1 4 44 36 — 4 22 231 256
West Virginia — 1 21 93 87 — 0 4 17 18 — 0 2 4 4
E.S. Central 8 20 50 980 214 1 2 8 98 116 24 18 39 716 924
Alabama§ — 0 0 — — — 0 0 — — 2 5 12 190 354
Kentucky — 3 16 152 58 — 0 2 13 7 5 2 13 104 50
Mississippi — 1 6 46 41 — 0 2 10 21 16 4 17 177 179
Tennessee§ 8 13 44 782 115 1 2 7 75 88 1 5 17 245 341
W.S. Central 15 18 91 1,419 100 1 5 41 229 276 7 37 58 1,459 2,278
Arkansas§ — 2 9 130 46 — 0 3 14 35 7 3 13 133 203
Louisiana — 1 8 67 54 — 0 3 20 22 — 7 24 317 645
Oklahoma — 1 5 40 — — 1 5 40 50 — 2 6 64 74
Texas§ 15 16 83 1,182 — 1 3 34 155 169 — 25 42 945 1,356
Mountain 19 22 82 1,397 93 1 5 12 188 232 1 9 23 389 430
Arizona 6 8 51 635 — 1 2 7 81 101 — 3 7 124 194
Colorado 12 7 20 423 — — 1 4 54 37 — 2 7 105 78
Idaho§ — 0 2 11 — — 0 2 5 7 — 0 1 2 3
Montana§ — 0 2 16 — — 0 1 1 — — 0 1 1 2
Nevada§ — 1 4 60 35 — 0 1 5 7 — 1 9 86 81
New Mexico§ — 2 9 119 — — 0 4 14 26 1 1 4 38 45
Utah — 2 9 123 49 — 1 4 25 53 — 1 4 33 24
Wyoming§ 1 0 1 10 9 — 0 1 3 1 — 0 0 — 3
Pacific 2 5 14 238 3 — 0 7 29 27 8 42 60 1,702 1,713
Alaska — 1 9 92 — — 0 5 18 18 — 0 1 1 —
California 2 3 12 146 — — 0 2 11 — 7 37 55 1,465 1,523
Hawaii — 0 0 — 3 — 0 1 — 9 — 0 3 27 29
Oregon — 0 0 — — — 0 0 — — 1 1 6 56 42
Washington — 0 0 — — — 0 0 — — — 3 10 153 119
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — 1 4 15 182 174
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending October 16, 2010, and October 17, 2009 (41st week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox)§ Neuroinvasive Nonneuroinvasive¶
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 127 312 547 11,125 16,974 — 0 68 479 381 — 1 48 310 333
New England 1 15 36 562 884 — 0 3 12 — — 0 1 2 —
Connecticut — 6 20 253 414 — 0 2 6 — — 0 1 1 —
Maine§ — 3 15 157 181 — 0 0 — — — 0 0 — —
Massachusetts — 0 0 — 4 — 0 2 5 — — 0 1 1 —
New Hampshire 1 2 8 106 171 — 0 1 1 — — 0 0 — —
Rhode Island§ — 1 12 27 31 — 0 0 — — — 0 0 — —
Vermont§ — 0 10 19 83 — 0 0 — — — 0 0 — —
Mid. Atlantic 13 32 62 1,245 1,702 — 0 19 119 9 — 0 13 56 1
New Jersey — 9 30 427 360 — 0 3 13 3 — 0 6 11 —
New York (Upstate) N 0 0 N N — 0 9 55 3 — 0 7 29 1
New York City — 0 0 — — — 0 7 32 3 — 0 4 8 —
Pennsylvania 13 21 39 818 1,342 — 0 3 19 — — 0 3 8 —
E.N. Central 47 103 176 3,720 5,271 — 0 13 60 9 — 0 6 24 4
Illinois 5 24 49 969 1,302 — 0 10 33 5 — 0 4 11 —
Indiana§ — 5 35 331 384 — 0 1 2 2 — 0 2 6 2
Michigan 8 33 62 1,102 1,508 — 0 6 23 1 — 0 1 4 —
Ohio 32 28 56 1,042 1,586 — 0 1 2 — — 0 1 1 2
Wisconsin 2 7 22 276 491 — 0 0 — 1 — 0 1 2 —
W.N. Central 9 15 40 619 1,085 — 0 7 25 26 — 0 8 60 74
Iowa N 0 0 N N — 0 1 2 — — 0 2 4 5
Kansas§ — 6 22 225 454 — 0 1 1 4 — 0 2 5 9
Minnesota — 0 0 — — — 0 1 3 1 — 0 1 2 3
Missouri 5 7 23 328 524 — 0 1 3 4 — 0 0 — 1
Nebraska§ N 0 0 N N — 0 3 10 11 — 0 7 27 40
North Dakota — 0 26 31 57 — 0 2 2 — — 0 1 6 1
South Dakota 4 0 7 35 50 — 0 2 4 6 — 0 3 16 15
S. Atlantic 29 37 98 1,733 2,165 — 0 4 22 16 — 0 4 12 2
Delaware§ — 0 3 15 11 — 0 0 — — — 0 0 — —
District of Columbia — 0 4 17 27 — 0 0 — 2 — 0 0 — —
Florida§ 7 15 57 846 1,009 — 0 2 6 2 — 0 1 1 1
Georgia N 0 0 N N — 0 1 4 4 — 0 3 7 —
Maryland§ N 0 0 N N — 0 3 10 — — 0 2 4 1
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina§ — 0 35 75 93 — 0 0 — 3 — 0 0 — —
Virginia§ 12 11 34 412 617 — 0 1 2 5 — 0 0 — —
West Virginia 10 8 26 368 408 — 0 0 — — — 0 0 — —
E.S. Central — 6 22 233 467 — 0 1 7 36 — 0 3 9 27
Alabama§ — 5 22 226 462 — 0 1 1 — — 0 1 2 —
Kentucky N 0 0 N N — 0 1 2 3 — 0 1 1 —
Mississippi — 0 2 7 5 — 0 1 2 29 — 0 2 4 22
Tennessee§ N 0 0 N N — 0 1 2 4 — 0 2 2 5
W.S. Central 23 50 285 2,168 4,174 — 0 14 73 116 — 0 3 13 35
Arkansas§ — 3 32 122 420 — 0 3 6 6 — 0 0 — —
Louisiana — 1 5 40 118 — 0 3 14 10 — 0 1 6 11
Oklahoma N 0 0 N N — 0 0 — 8 — 0 0 — 2
Texas§ 23 41 272 2,006 3,636 — 0 14 53 92 — 0 2 7 22
Mountain 5 20 36 801 1,134 — 0 13 119 77 — 0 15 111 123
Arizona — 0 0 — — — 0 10 80 12 — 0 9 52 8
Colorado§ 5 8 16 322 437 — 0 5 24 36 — 0 11 49 67
Idaho§ N 0 0 N N — 0 0 — 9 — 0 1 1 29
Montana§ — 3 17 161 129 — 0 0 — 2 — 0 0 — 3
Nevada§ N 0 0 N N — 0 0 — 7 — 0 1 2 5
New Mexico§ — 2 8 87 100 — 0 4 13 6 — 0 2 3 2
Utah — 5 17 218 468 — 0 0 — 1 — 0 0 — 1
Wyoming§ — 0 3 13 — — 0 1 2 4 — 0 1 4 8
Pacific — 1 5 44 92 — 0 7 42 92 — 0 4 23 67
Alaska — 0 5 33 54 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 7 42 65 — 0 4 23 45
Hawaii — 0 2 11 38 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 0 — 1 — 0 0 — 10
Washington N 0 0 N N — 0 0 — 26 — 0 0 — 12
Territories
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 3 14 20 — 0 0 — — — 0 0 — —
Puerto Rico 9 9 30 486 465 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting year 2010 is provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
¶ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis.htm.
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TABLE III. Deaths in 122 U.S. cities,* week ending October 16, 2010 (41st week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 512 364 104 26 7 11 34 S. Atlantic 1,152 728 305 72 29 17 80
Boston, MA 140 93 33 8 2 4 7 Atlanta, GA 123 69 39 11 3 1 8
Bridgeport, CT 27 22 4 1 — — 2 Baltimore, MD 144 82 45 14 2 1 10
Cambridge, MA 18 14 4 — — — 3 Charlotte, NC 137 102 28 7 — — 12
Fall River, MA 24 21 3 — — — 1 Jacksonville, FL 153 104 38 6 3 2 10
Hartford, CT 40 28 7 4 — 1 4 Miami, FL 78 48 20 5 3 2 11
Lowell, MA 18 13 1 1 1 2 1 Norfolk, VA 59 34 15 4 2 4 2
Lynn, MA 9 5 2 2 — — — Richmond, VA 67 39 22 2 4 — 8
New Bedford, MA 12 11 1 — — — 2 Savannah, GA 54 42 7 2 1 2 —
New Haven, CT 35 23 8 3 — 1 2 St. Petersburg, FL 55 37 12 2 2 2 1
Providence, RI 70 53 13 2 1 1 4 Tampa, FL 165 107 45 8 2 3 12
Somerville, MA 5 3 1 1 — — — Washington, D.C. 111 61 33 9 7 — 5
Springfield, MA 30 19 11 — — — — Wilmington, DE 6 3 1 2 — — 1
Waterbury, CT 24 15 7 — 2 — 5 E.S. Central 710 445 178 48 24 15 63
Worcester, MA 60 44 9 4 1 2 3 Birmingham, AL 145 91 31 11 7 5 12
Mid. Atlantic 1,693 1,197 345 95 35 21 84 Chattanooga, TN 74 61 8 3 2 — 4
Albany, NY 43 34 7 2 — — 1 Knoxville, TN 69 47 14 6 1 1 5
Allentown, PA 31 25 3 2 — 1 1 Lexington, KY 80 47 25 5 3 — 3
Buffalo, NY 81 50 24 4 2 1 4 Memphis, TN 136 82 39 9 3 3 18
Camden, NJ 29 17 10 2 — — 2 Mobile, AL 48 27 15 3 1 2 3
Elizabeth, NJ 14 8 5 — 1 — 2 Montgomery, AL 27 18 8 — — 1 5
Erie, PA 46 34 9 3 — — 2 Nashville, TN 131 72 38 11 7 3 13
Jersey City, NJ 30 19 6 5 — — 1 W.S. Central 1,226 772 299 102 31 22 72
New York City, NY 942 680 183 50 19 10 36 Austin, TX 53 32 18 3 — — 2
Newark, NJ U U U U U U U Baton Rouge, LA U U U U U U U
Paterson, NJ 17 8 8 1 — — 3 Corpus Christi, TX 56 34 17 3 2 — 4
Philadelphia, PA 146 85 35 13 5 8 8 Dallas, TX 183 119 44 10 7 3 14
Pittsburgh, PA§ 40 27 10 1 2 — 4 El Paso, TX 73 55 9 4 4 1 6
Reading, PA 26 23 2 — 1 — 2 Fort Worth, TX U U U U U U U
Rochester, NY 72 52 15 — 4 1 7 Houston, TX 430 239 107 67 12 5 26
Schenectady, NY 24 18 4 2 — — 2 Little Rock, AR 59 40 16 1 1 1 —
Scranton, PA 21 15 5 — 1 — 2 New Orleans, LA U U U U U U U
Syracuse, NY 71 59 10 2 — — 4 San Antonio, TX 208 135 48 11 3 11 11
Trenton, NJ 22 15 4 3 — — — Shreveport, LA 50 39 10 — 1 — 3
Utica, NY 21 17 1 3 — — 1 Tulsa, OK 114 79 30 3 1 1 6
Yonkers, NY 17 11 4 2 — — 2 Mountain 1,059 685 252 64 35 21 60
E.N. Central 1,834 1,217 467 93 23 34 117 Albuquerque, NM 109 75 23 5 4 2 9
Akron, OH 44 29 8 4 1 2 6 Boise, ID 47 33 10 3 1 — 3
Canton, OH 29 19 7 2 1 — 7 Colorado Springs, CO 60 39 15 3 3 — 1
Chicago, IL 238 131 81 21 5 — 23 Denver, CO 78 43 23 5 2 5 3
Cincinnati, OH 87 57 17 9 — 4 9 Las Vegas, NV 308 180 94 15 12 7 17
Cleveland, OH 233 167 58 4 1 3 9 Ogden, UT 23 17 4 2 — — 2
Columbus, OH 176 129 37 3 1 6 9 Phoenix, AZ 176 113 36 13 8 4 10
Dayton, OH 143 103 31 7 2 — 9 Pueblo, CO 33 29 3 1 — — 1
Detroit, MI 117 69 36 6 3 3 2 Salt Lake City, UT 110 75 22 10 1 2 9
Evansville, IN 44 32 11 1 — — 2 Tucson, AZ 115 81 22 7 4 1 5
Fort Wayne, IN 55 37 15 2 — 1 2 Pacific 1,505 1,019 354 73 30 28 116
Gary, IN 18 5 9 4 — — — Berkeley, CA 11 8 2 — 1 — 1
Grand Rapids, MI 55 41 13 — — 1 2 Fresno, CA 107 67 26 6 4 4 6
Indianapolis, IN 191 116 55 11 3 6 7 Glendale, CA 32 27 3 — — 2 5
Lansing, MI 47 34 11 — 1 1 4 Honolulu, HI 82 59 14 6 — 3 7
Milwaukee, WI 80 51 20 7 — 2 6 Long Beach, CA 67 39 19 3 3 3 8
Peoria, IL 42 28 9 2 1 2 7 Los Angeles, CA 221 134 60 17 6 4 19
Rockford, IL 61 39 15 4 2 1 3 Pasadena, CA 18 15 1 2 — — 2
South Bend, IN 36 29 7 — — — 3 Portland, OR 115 74 32 8 1 — 7
Toledo, OH 77 53 15 5 2 2 2 Sacramento, CA 141 100 32 6 — 2 12
Youngstown, OH 61 48 12 1 — — 5 San Diego, CA 147 97 37 9 3 1 6
W.N. Central 562 386 128 34 10 4 37 San Francisco, CA 98 72 24 — 1 1 10
Des Moines, IA 78 54 20 3 1 — 4 San Jose, CA 159 125 26 3 2 3 15
Duluth, MN 31 24 7 — — — 1 Santa Cruz, CA 23 17 5 — 1 — 1
Kansas City, KS 26 16 5 5 — — 1 Seattle, WA 94 61 25 5 1 2 7
Kansas City, MO 120 81 26 9 1 3 8 Spokane, WA 61 41 14 3 3 — 7
Lincoln, NE 35 26 9 — — — 2 Tacoma, WA 129 83 34 5 4 3 3
Minneapolis, MN 47 31 9 3 3 1 3 Total¶ 10,253 6,813 2,432 607 224 173 663
Omaha, NE 86 57 21 5 3 — 6
St. Louis, MO 15 6 4 4 1 — —
St. Paul, MN 51 39 10 2 — — 4
Wichita, KS 73 52 17 3 1 — 8
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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